

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEx enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 19	APOLLIT offering free connect time in April 2003
NEWS	28	Mar 20	EVENTLINE will be removed from STN
NEWS	29	Mar 24	PATDPAFULL now available on STN
NEWS	30	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	31	Mar 24	Indexing from 1957 to 1966 added to records in CA/CAPLUS
NEWS	32	Apr 11	Display formats in DGENE enhanced
NEWS	33	Apr 14	MEDLINE Reload
NEWS EXPRESS			April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:42:43 ON 15 APR 2003

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 08:42:51 ON 15 APR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 APR 2003 HIGHEST RN 502958-40-9

DICTIONARY FILE UPDATES: 14 APR 2003 HIGHEST RN 502958-40-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 10002326.9

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 08:43:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2 TO 124
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 08:43:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 39 TO ITERATE

100.0% PROCESSED 39 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L3 1 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	148.36

FILE 'CAPLUS' ENTERED AT 08:43:33 ON 15 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Apr 2003 VOL 138 ISS 16
FILE LAST UPDATED: 14 Apr 2003 (20030414/ED)


This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 2 L3

=> d l4 fbib hitstr abs total

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 1960:110543 CAPLUS
DN 54:110543
OREF 54:21090b-i,21091a-e
TI Pyridine analogs of p-terphenyl and p-quaterphenyl
AU Wiley, Richard H.; Callahan, P. X.; Jarboe, C. H.; Nielsen, J. T.; Wakefield, B. J.
CS Univ. of Louisville, Louisville, KY
SO J. Org. Chem. (1960), 25, 366-71
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA Unavailable
IT **101884-39-3**, Picolinic acid, 3-(o-carboxyphenyl)-6-phenyl- (prepn. of)
RN 101884-39-3 CAPLUS
CN Picolinic acid, 3-(o-carboxyphenyl)-6-phenyl- (6CI) (CA INDEX NAME)




AB A no. of analogs of p-terphenyl and p-quaterphenyl were prepd. for evaluation as scintillation solutes. BuLi (from 4.4 g. Li and 40 g. BuBr in 350 ml. dry Et₂O) cooled in a Dry Ice-Me₂CO bath, treated with 30 g. 3-bromopyridine and 28.6 g. cyclohexanone, gave after 3 hrs. 21 g. 3-(1-cyclohexen-1-yl)pyridine (I), b₂ 98-101.degree., n_{25D} 1.5683. S (4.5 g.) and 12.0 g. I refluxed 2 hrs. gave 4.5 g. 3-phenylpyridine (II), b. 273-4.degree., n_{23D} 1.6142. I (1 g.) with N passed through Al₂O₃-Pd in a Pyrex glass tube at 360.degree. gave 0.5 g. II. II was also prepd. by oxidn. of benzo[f]quinoline (III) with KMnO₄ [Skraup and Cobenzyl, Monatsh. 4, 450, 442, 456(1884)] and by coupling PhNacNO with C₅H₅N (Farley and Eliel, CA 51, 1161f). PhLi (from 0.15 g. Li and 1.6 g. PhBr in 150 ml. Et₂O) added to 2.55 g. III in 150 ml. Et₂O in an N atm. and the

mixt. stirred 10 hrs. and poured into excess cold dil. HCl, gave 2-phenylbenzo[f]quinoline-HCl (IV.HCl), m. 215-25.degree. (decompn.) (dil. HCl); IV m. 188-8.5.degree.. II (2.50 g.) in 150 ml. dry Et2O treated with 150 ml. Et2O contg. PhLi (from 2.71 g. PhBr) and the mixt. stirred 24 hrs. at room temp., gave 0.95 g. 2,5-diphenylpyridine (V), m. 174-5.degree. (EtOH). Finely divided IV (1.6 g.) suspended in 700 ml. H2O contg. 0.87 g. NaOH, the mixt. heated to 90-100.degree., treated portionwise with 2.26 g. KMnO4, stirred 4 days at 90-100.degree., filtered, the filtrate made neutral to phenolphthalein with dil. H2SO4, concd. to 2.5 ml., dild. with 40 ml. EtOH, the pptd. K2SO4 filtered off, the filtrate evapd. to dryness, and the residue recrystd. from C6H6 gave 1.6 g. 3-(o-carboxyphenyl)-6-phenyl-2-carboxypyridine (VI), m. 196.degree. (decompn.). VI (1.5 g.) decarboxylated by heating 25 min. at 200.degree. gave 1.2 g. 5-(o-carboxyphenyl)-2-phenylpyridine (VII), m. 195-6.degree. (EtOH), mixed m.p. with VI depressed. VII (0.3 g.) ground with a large excess Cu dust, the mixt. heated to redness in a Cu test tube, the residue extd. with C6H6, the ext. evapd., and the residue recrystd. from EtOH gave 0.2 g. V, m. 174.degree.. p-Me2NC6H4Li soln. (from 2 g. p-Me2NC6H4Br) added to II in dry Et2O kept 3 days in an N atm., poured into excess dil. HCl, the Et2O evapd., the soln. neutralized with aq. NaOH, extd. with hot C6H6, and the exts. evapd. gave 0.39 g. 2-(p-dimethylaminophenyl)-5-phenylpyridine (VIII), m. 201.degree. (EtOH). Diazotized p-O2NC6H4NH2 coupled with C5H5N (method of Haworth, et al., CA 34, 37433) gave 36% 2-(p-nitrophenyl)pyridine (IX), m. 130-1.degree., and 15% 3-(p-nitrophenyl)pyridine (X), m. 146-7.degree.. Fractions thought to contain a high proportion of 4-isomer (XI) converted to the picrates, gave a more-sol. picrate (mainly of IX), m. 157-60.degree. (Me2CO), and a less-sol. XI picrate, m. 225-7.degree. (Me2CO); XI m. 122-4.degree.. IX, X, and XI reduced with Sn and HCl (Forsyth and Pyman, CA 21, 585) gave 86% 2-(XII), m. 96-7.degree., 60% 3-(XIII), m. 99-101.degree. (with H2O of crystn.) (anhyd. XIII m. 116-18.degree.), and 40% 4-(p-aminophenyl)pyridine (XIV), m. 232-4.degree., resp. XII (14.5 g.) in 55 ml. concd. HCl and 25 ml. H2O cooled to 0.degree., treated slowly below 5.degree. with 7.0 g. NaNO2 in 15 ml. H2O with stirring, the soln. stirred 15 min., added to 250 ml. C5H5N with stirring at 35-40.degree., the mixt. heated 30 min. at 80.degree., cooled, poured into 2.5 l. cold H2O, the ppt. filtered off, washed free from C5H5N with cold H2O, air dried, the product (16 g.) dissolved in 70 ml. EtOH (a small amt. insol. material was discarded), and the soln. progressively concd. and dild. with H2O and the fractions obtained chromatographed yielded 14 mg. p-bis(2-pyridyl)benzene (XV), m. 146-8.degree., and 50 mg. 1-(2-pyridyl)-4-(4-pyridyl)benzene (XVI), m. 191-3.degree.. Rechromatography of residues gave addnl. small amts. XV and XVI. By this process was isolated 30% XV, m. 1478.degree. (MeCN), and 5% XVI, m. 196-7.degree. (PhMe). Anhyd. XIII (5.5 g.) diazotized and coupled with C5H5N gave from a 0.5 g. sample of intermediate fraction 0.29 g. (crude) 1-(2-pyridyl)-4-(3-pyridyl)benzene, m. 131.5-2.0.degree. (MeCN), XIV (0.8 g.) diazotized and coupled with C5H5N gave 0.6 g. crude product, 112 mg. of which was chromatographed to give 51 mg. XVI. Ph2 (60 g.) nitrated with concd. HNO3 at 45.degree. (Gull and Turner; CA 23, 2962) gave 29 g. (4-O2NC6H4)2 (XVII), m. 225-30.degree.. XVII (29 g.) reduced with aq. Na polysulfide (Belcher, et al., CA 47, 9207f) gave 13 g. 4-O2NC6H4C6H4NH2-4 (XVIII), m. 201-3.degree.. XVIII (13 g.) in 80 ml. AcOH cooled to 10.degree., treated during 15 min. with 3.9 g. finely divided NaNO2 with vigorous stirring below 15.degree., the soln. stirred 15 min., added to 200 ml. C5H5N at 35-40.degree., the whole heated 30 min. on a steam bath, poured into 1500 ml. H2O, the ppt. filtered off, washed, air dried, and the product (14.5 g.) fractionally recrystd. from PhMe gave 1.9 g. 4-nitro-4'-(2-

pyridyl)biphenyl (XIX), m. 214-15.degree.. XIX (1.7 g.) reduced by SnCl₂ and HCl (Heilbron, et al., CA 35, 1149) gave 1.1 g. 4-amino-4'-(2-pyridyl)biphenyl, m. 192-3.degree.; Ac deriv. (XX) m. 235-7.degree.. XX (0.9 g.) in 5 ml. AcOH and 3 ml. AcOH mixed with 1 g. anhyd. KOAc and a few mg. P₂O₅, cooled to 5.degree., treated dropwise with 0.6 g. redistd. NOCl and 0.6 g. Ac₂O, the soln. stirred 15 min., poured into 50 ml. ice H₂O, the mixt. extd. with 50 ml. C₆H₆, treated with Na₂CO₃, again extd. with 50 ml. C₆H₆, the C₆H₆ exts. combined, washed with H₂O, dried overnight, the C₆H₆ distd., the residue (0.8 g.) chromatographed on acid Al₂O₃ gave from C₆H₆ 0.10 g. 4-(2-pyridyl)p-terphenyl (XXI), m. 269-70.degree. (C₆H₆). Li (0.14 g.) suspended in 200 ml. dry Et₂O in an N atm. (the reaction was carried out in a dry box), cooled to -65.degree., treated dropwise with 1.37 g. BuBr with stirring, treated with 2.33 g. 4BrC₆H₄Ph, the mixt. stirred 30 min. at -65.degree., treated with 1.5 g. II, the whole allowed to warm to room temp., stand overnight, and worked up gave 0.5 g. 2-(4-biphenyl)5-phenylpyridine (XXII), m. 274-5.degree. (C₆H₆), 280 (shoulder) and 307 m.mu. (log .epsilon. 4.47 and 4.63). The scintillation data obtained with some of the compds. were as follows [compd., relative pulse ht. (relative to 3 g. 2,5-diphenyloxazole/1. PhMe), concn. (g./l.), soly. (g./l.) in PhMe at 25.degree. given]: p-terphenyl, 0.94, 3, 8; 4-(2-pyridyl)biphenyl, 0.12, 3, -; V, <0.10, 3, 13; VIII, 0.94, 3, -; XVI, <0.10, 3, -; p-quaterphenyl., -, -, <1; XXI, 0.70, 1.02, 1.02; XXII, 0.41, 1.8, 1.8. The results indicated that while the introduction of a pyridine nucleus into a polyphenyl increased its soly. in PhMe, this advantage was overshadowed by a great redn. in scintillation response. Ultraviolet data were listed for V, VIII, XV, XVI, and 1-(2-pyridyl)-4-(3-pyridyl)benzene.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
 AN 1959:77794 CAPLUS
 DN 53:77794
 OREF 53:14102c-e
 TI Specificity of phenyllithium addition reactions
 AU Wiley, Richard H.; Jarboe, Charles H.; Callahan, Paul X.; Nielsen, Jorgen T.
 CS Univ. of Louisville, Louisville, KY
 SO J. Org. Chem. (1958), 23, 780
 CODEN: JOCEAH; ISSN: 0022-3263
 DT Journal
 LA Unavailable
 IT 101884-39-3, Picolinic acid, 3-(o-carboxyphenyl)-6-phenyl- (prepn. of)
 RN 101884-39-3 CAPLUS
 CN Picolinic acid, 3-(o-carboxyphenyl)-6-phenyl- (6CI) (CA INDEX NAME)



AB PhLi added to 3-phenylpyridine in Na-dried Et₂O under O-free N, the mixt. kept 24 hrs. at room temp., the crude product isolated from the H₂O-washed Et₂O soln., placed in C₆H₆, and passed through a column of acidic Al₂O₃ gave 2,5-diphenylpyridine (I), m. 174-5.degree., .nu. 1580, 1470, 1460,

1370, 1072, 1017, 1003, 905, 835, 752, 735, 687 cm.⁻¹ Alk. KMnO₄ oxidation of 3-benzo[f]quinoline gave 2-phenyl-5-(.omicron.-carboxyphenyl)-6-carboxypyridine, m. 196.degree., which was decarboxylated to 2-phenyl-5-(.omicron.-carboxyphenyl)pyridine (II), m. 195.degree.. II pyrolyzed with electrolytic Cu in an O-free N atm. gave I, m. 174.degree., mixed m.p. with above material 174.degree..

Welcome to STN International! Enter x:x

LOGINID:sssptal611sxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Jun 03 New e-mail delivery for search results now available
NEWS 4 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 6 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 7 Sep 03 JAPIO has been reloaded and enhanced
NEWS 8 Sep 16 Experimental properties added to the REGISTRY file
NEWS 9 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 10 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11 Oct 24 BEILSTEIN adds new search fields
NEWS 12 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13 Nov 18 DKILIT has been renamed APOLLIT
NEWS 14 Nov 25 More calculated properties added to REGISTRY
NEWS 15 Dec 04 CSA files on STN
NEWS 16 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17 Dec 17 TOXCENTER enhanced with additional content
NEWS 18 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 19 Jan 29 Simultaneous left and right truncation added to COMPENDEX,
ENERGY, INSPEC
NEWS 20 Feb 13 CANCERLIT is no longer being updated
NEWS 21 Feb 24 METADEX enhancements
NEWS 22 Feb 24 PCTGEN now available on STN
NEWS 23 Feb 24 TEMA now available on STN
NEWS 24 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 25 Feb 26 PCTFULL now contains images
NEWS 26 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27 Mar 19 APOLLIT offering free connect time in April 2003
NEWS 28 Mar 20 EVENTLINE will be removed from STN
NEWS 29 Mar 24 PATDPAFULL now available on STN
NEWS 30 Mar 24 Additional information for trade-named substances without
structures available in REGISTRY
NEWS 31 Mar 24 Indexing from 1957 to 1966 added to records in CA/CAPLUS
NEWS 32 Apr 11 Display formats in DGENE enhanced

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:15:24 ON 14 APR 2003

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 07:15:36 ON 14 APR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 APR 2003 HIGHEST RN 502841-39-6

DICTIONARY FILE UPDATES: 13 APR 2003 HIGHEST RN 502841-39-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 10002326.3

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

FILE 'CAPLUS' ENTERED AT 07:16:29 ON 14 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Apr 2003 VOL 138 ISS 16
FILE LAST UPDATED: 13 Apr 2003 (20030413/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 18 L3

=> s 14 fbib hitstr abs total

MISSING OPERATOR L4 FBIB

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> d 14 fbib hitstr abs total

L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2003 ACS

AN 2003:196948 CAPLUS

DN 138:221357

TI Preparation of 2'-aminomethylbiphenyl-2-carboxamides as Kv1.5 potassium channel blockers

IN Brendel, Joachim; Schmidt, Wolfgang; Below, Peter

PA Aventis Pharma Deutschland GmbH, Germany

SO U.S., 65 pp., Cont.-in-part of U.S. Ser. No. 675,674.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6531495	B1	20030311	US 2000-698078	20001030
				DE 1999-19947457A	19991002
				US 2000-675674	A220000929
				DE 1999-19947457	19991002

PATENT FAMILY INFORMATION:

FAN 2001:239812

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19947457	A1	20010405	DE 1999-19947457	19991002
	WO 2001025189	A1	20010412	WO 2000-EP9151	20000919

Patel

<4/14/2003>

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 1999-19947457A 19991002
 BR 2000014465 A 20020611 BR 2000-14465 20000919
 DE 1999-19947457A 19991002
 WO 2000-EP9151 W 20000919
 EP 1222163 A1 20020717 EP 2000-967703 20000919
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL
 DE 1999-19947457A 19991002
 WO 2000-EP9151 W 20000919
 JP 2003511363 T2 20030325 JP 2001-528137 20000919
 DE 1999-19947457A 19991002
 WO 2000-EP9151 W 20000919
 US 6531495 B1 20030311 US 2000-698078 20001030
 DE 1999-19947457A 19991002
 US 2000-675674 A220000929
 NO 2002001398 A 20020531 NO 2002-1398 20020320
 DE 1999-19947457A 19991002
 WO 2000-EP9151 W 20000919

FAN 2003:193044

PATENT NO.

KIND DATE

APPLICATION NO. DATE

PI WO 2001025189 A1 20010412 WO 2000-EP9151 20000919
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 DE 1999-19947457A 19991002
 DE 19947457 A1 20010405 DE 1999-19947457 19991002
 BR 2000014465 A 20020611 BR 2000-14465 20000919
 DE 1999-19947457A 19991002
 WO 2000-EP9151 W 20000919
 EP 1222163 A1 20020717 EP 2000-967703 20000919
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL
 DE 1999-19947457A 19991002
 WO 2000-EP9151 W 20000919
 JP 2003511363 T2 20030325 JP 2001-528137 20000919
 DE 1999-19947457A 19991002
 WO 2000-EP9151 W 20000919
 NO 2002001398 A 20020531 NO 2002-1398 20020320
 DE 1999-19947457A 19991002
 WO 2000-EP9151 W 20000919

OS MARPAT 138:221357


IT 332378-39-9P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(antiarrhythmic; prepn. of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)

RN 332378-39-9 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1-[4-(trifluoromethyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)



IT 498577-28-9P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antiarrhythmic; prepn. of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)

RN 498577-28-9 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1S)-1-[4-(trifluoromethyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 498578-50-0P 498578-51-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(antiarrhythmic; prepn. of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)


RN 498578-50-0 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methylbutyl)amino]carbonyl]-4'-nitro[1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 498578-51-1 CAPLUS

CN Carbamic acid, [[4'-methoxy-2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 332378-34-4P 332378-35-5P 332378-36-6P
 332378-37-7P 332378-38-8P 332378-40-2P
 332378-41-3P 332378-42-4P 332378-43-5P
 332378-44-6P 332378-45-7P 332378-46-8P
 332378-47-9P 332378-48-0P 332378-49-1P
 332378-69-5P 332378-70-8P 332378-71-9P
 332378-72-0P 332378-73-1P 332378-74-2P
 332378-75-3P 332378-76-4P 332378-77-5P
 332378-78-6P 332378-79-7P 332378-80-0P
 332378-81-1P 332378-82-2P 498577-29-0P
 498577-30-3P 498577-31-4P 498577-32-5P
 498577-33-6P 498577-34-7P 498577-35-8P
 498577-36-9P 498577-37-0P 498577-38-1P
 498577-39-2P 498577-40-5P 498577-41-6P
 498577-42-7P 498577-43-8P 498577-44-9P
 498577-46-1P 498577-48-3P 498577-49-4P
 498577-50-7P 498577-51-8P 498577-52-9P
 498577-53-0P 498577-54-1P 498577-55-2P
 498577-56-3P 498577-57-4P 498577-58-5P


498577-59-6P 498577-60-9P 498577-61-0P
 498577-62-1P 498577-63-2P 498577-64-3P
 498577-65-4P 498577-66-5P 498577-67-6P
 498577-68-7P 498577-69-8P 498577-70-1P
 498577-71-2P 498577-72-3P 498577-73-4P
 498577-74-5P 498577-75-6P 498577-76-7P
 498577-77-8P 498577-78-9P 498577-79-0P
 498577-80-3P 498577-81-4P 498577-82-5P
 498577-83-6P 498577-84-7P 498577-85-8P
 498577-86-9P 498577-87-0P 498577-88-1P
 498577-89-2P 498577-90-5P 498577-91-6P
 498577-92-7P 498577-93-8P 498577-94-9P
 498577-95-0P 498577-96-1P 498577-97-2P
 498577-98-3P 498577-99-4P 498578-00-0P
 498578-01-1P 498578-02-2P 498578-04-4P
 498578-05-5P 498578-06-6P 498578-07-7P
 498578-08-8P 498578-09-9P 498578-10-2P
 498578-11-3P 498578-12-4P 498578-13-5P
 498578-14-6P 498578-15-7P 498578-16-8P
 498578-17-9P 498578-18-0P 498578-19-1P
 498578-20-4P 498578-21-5P 498578-35-1P
 498578-36-2P 498578-37-3P 498578-38-4P
 498578-39-5P 498578-40-8P 498578-42-0P
 498578-44-2P 498578-45-3P 498578-46-4P
 498578-47-5P 498578-48-6P 498578-49-7P
 498578-52-2P 498578-53-3P 498578-62-4P
 498578-63-5P 498578-65-7P 498578-66-8P
 498578-68-0P 498578-70-4P 498578-71-5P
 498578-72-6P 498578-74-8P 498578-76-0P
 498578-77-1P 498578-80-6P 498578-81-7P
 498578-82-8P 498578-83-9P 498578-84-0P
 498578-85-1P 498578-87-3P 498578-89-5P
 498578-92-0P 498578-95-3P 498578-96-4P
 498578-98-6P 498578-99-7P 498579-00-3P
 498579-01-4P 498579-04-7P 498579-07-0P
 498579-09-2P 498579-13-8P 498579-15-0P
 498579-18-3P 498579-21-8P 498579-43-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(antiarrhythmic; prepn. of aminomethylbiphenylcarboxamides as Kv1.5
 potassium channel blockers)


RN 332378-34-4 CAPLUS

CN Carbamic acid, [[2'-[[[(2'-phenylethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, [4-(trifluoromethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 332378-35-5 CAPLUS

CN Carbamic acid, [[2'-[[[(2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-36-6 CAPLUS

CN Carbamic acid, [[2'-[[[(2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 2-(methylsulfonyl)ethyl ester (9CI) (CA INDEX NAME)




RN 332378-37-7 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, [4-(trifluoromethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 332378-38-8 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (4-fluorophenyl)methyl ester (9CI) (CA INDEX NAME)




RN 332378-40-2 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 4,4,4-trifluorobutyl ester (9CI) (CA INDEX NAME)




RN 332378-41-3 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, butyl ester (9CI) (CA INDEX NAME)




RN 332378-42-4 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-43-5 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-44-6 CAPLUS

CN Carbamic acid, [[2'-[[[3-methylbutyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, butyl ester (9CI) (CA INDEX NAME)




RN 332378-45-7 CAPLUS

CN Carbamic acid, [[2'-[[[3-methylbutyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (2-chlorophenyl)methyl ester (9CI) (CA INDEX NAME)




RN 332378-46-8 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 332378-47-9 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 332378-48-0 CAPLUS

CN Benzoic acid, 4-[[[2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]amino]carbonyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 332378-49-1 CAPLUS

CN Carbamic acid, [[2'-[[[(2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)




RN 332378-69-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[(benzoylamino)methyl]-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 332378-70-8 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, 2'--[(benzoylamino)methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 332378-71-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(3-methylbutyl)-2'-
[[[(phenylamino)carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)


RN 332378-72-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(phenylamino)carbonyl]amino]methyl]-N-
[2'-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

RN 332378-73-1 CAPLUS


CN Carbamic acid, [[2'-[[methyl(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-2-

yl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-74-2 CAPLUS

CN Carbamic acid, [[2'-[(cyclohexylamino)carbonyl][1,1'-biphenyl]-2-yl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-75-3 CAPLUS

CN Carbamic acid, [[2'-[(phenylamino)carbonyl][1,1'-biphenyl]-2-yl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-76-4 CAPLUS

CN Carbamic acid, [[2'-[[methyl[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-77-5 CAPLUS

CN Carbamic acid, [[2'-[(dibutylamino)carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-78-6 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-79-7 CAPLUS

CN Carbamic acid, [[2'-[[[(2,2,2-trifluoroethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 332378-80-0 CAPLUS


CN Carbamic acid, [[2'-[[[2-(1-oxido-2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 332378-81-1 CAPLUS

CN Carbamic acid, [[2'-[[[[(1S)-1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 332378-82-2 CAPLUS

CN L-Phenylalanine, N-[[2'-[[[(phenylmethoxy)carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

biphenyl]-2-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 498577-29-0 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1S)-1-phenylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 498577-30-3 CAPLUS


CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1R)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498577-31-4 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1-[2-(trifluoromethyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)




RN 498577-32-5 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1-[3-(trifluoromethyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)



RN 498577-33-6 CAPLUS


CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1-(2,6-difluorophenyl)ethyl ester (9CI) (CA INDEX NAME)



RN 498577-34-7 CAPLUS



CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1R)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498577-35-8 CAPLUS


CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1-[4-(trifluoromethyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)



RN 498577-36-9 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1S)-1-phenylbutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498577-37-0 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1S)-1-phenylbutyl ester (9CI) (CA INDEX NAME)


2-yl)methyl]-, (1S)-1-phenylbutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498577-38-1 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl)methyl]-, (4-fluorophenyl)methyl ester (9CI) (CA INDEX NAME)




RN 498577-39-2 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl)methyl]-, 4,4,4-trifluorobutyl ester (9CI) (CA INDEX NAME)




RN 498577-40-5 CAPLUS

CN Carbamic acid, [[2'-[[[(2-pyridinylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 498577-41-6 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)





RN 498577-42-7 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenyl ester (9CI) (CA INDEX NAME)





RN 498577-43-8 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)





RN 498577-44-9 CAPLUS

CN Carbamic acid, [[2'-[[[(2-pyridinylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)




RN 498577-46-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498577-48-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)





RN 498577-49-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)





RN 498577-50-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 498577-51-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(4-methoxyphenyl)-2'--[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498577-52-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(4-methoxyphenyl)-2'--[[[(1-oxo-3-phenylpropyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 498577-53-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 498577-54-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 498577-55-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[3-(4-ethoxyphenyl)-1-oxopropyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 498577-56-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(1-oxo-3-phenylbutyl)amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 498577-57-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(phenylmethyl)amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 498577-58-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(1S)-1-phenylethyl]amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 498577-59-6 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(1R)-1-phenylethyl]amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498577-60-9 CAPLUS

CN Carbamic acid, [[2'-[[[2-(1-oxido-4-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 498577-61-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(1-oxido-3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 498577-62-1 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-63-2 CAPLUS

CN Carbamic acid, [[2'-[[[(2-pyridinylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-64-3 CAPLUS


CN Carbamic acid, [[2'-[[[(3-pyridinylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 498577-65-4 CAPLUS


CN Carbamic acid, [[2'-[[[2-(3-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)






RN 498577-66-5 CAPLUS

CN Carbamic acid, [[2'-[[[2-(4-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-67-6 CAPLUS

CN Carbamic acid, [[2'-[[[4-ethylphenyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-68-7 CAPLUS

CN Carbamic acid, [[2'-[[[4-methoxyphenyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-69-8 CAPLUS

CN Carbamic acid, [[2'-[[[(4-fluorophenyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 498577-70-1 CAPLUS


CN Carbamic acid, [[2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 498577-71-2 CAPLUS


CN Carbamic acid, [[2'-[[[(1R)-1-(hydroxymethyl)-2-phenylethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498577-72-3 CAPLUS

CN 2-Pyridinepropanoic acid, .alpha.-[[[2'-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 498577-73-4 CAPLUS


CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 498577-74-5 CAPLUS


CN Carbamic acid, [[2'-[[[(1S)-1-(aminocarbonyl)-2-methylpropyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498577-75-6 CAPLUS


CN Carbamic acid, [[2'-[[ethyl(4-pyridinylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 498577-76-7 CAPLUS


CN L-Leucine, N-[[2'-[[[(phenylmethoxy)carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498577-77-8 CAPLUS

CN Carbamic acid, [[2'-[[[(4,4,4-trifluorobutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 498577-78-9 CAPLUS

CN Carbamic acid, [[2'-[[[[4-(dimethylamino)phenyl]methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 498577-79-0 CAPLUS

CN Carbamic acid, [[2'-[[[2-[(1-methylethyl)amino]-2-oxoethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 498577-80-3 CAPLUS

CN 2-Pyridinepropanoic acid, .alpha.-[[[2'-[[[(phenylmethoxy)carbonyl]amino]methyl]ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 498577-81-4 CAPLUS

CN Carbamic acid, [[2'-[[[2-(3-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 498577-82-5 CAPLUS


CN Carbamic acid, [[2'-[[[2-(4-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 498577-83-6 CAPLUS


CN Carbamic acid, [[2'-[[[(1R)-1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498577-84-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-2'-[[[(phenylmethyl)amino]thioxomethyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498577-85-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(phenylamino)thioxomethyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 498577-86-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[thioxo[[3-(trifluoromethyl)phenyl]amino]methyl]amino]methyl]-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 498577-87-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(3,4-dichlorophenyl)amino]thioxomethyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 498577-88-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(phenylmethyl)amino]thioxomethyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 498577-89-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(2-phenylethyl)amino]thioxomethyl]amino]methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 498577-90-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(3-fluorophenyl)amino]thioxomethyl]amino]methyl]-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 498577-91-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-2'--[[[(3-fluorophenyl)amino]thioxomethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498577-92-7 CAPLUS

CN Carbamic acid, [[2'--[[[(2-methoxyethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-93-8 CAPLUS

CN Carbamic acid, [[2'-[[[(3,4,5-trimethoxyphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-94-9 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-methoxyphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-95-0 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2,4-dichlorophenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-96-1 CAPLUS

CN Carbamic acid, [[2'-[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-97-2 CAPLUS

CN Carbamic acid, [[2'-[[[2-phenoxyethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-98-3 CAPLUS

CN Carbamic acid, [[2'-[[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-99-4 CAPLUS

CN Carbamic acid, [[2'-[[[2-(thienylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498578-00-0 CAPLUS

CN Carbamic acid, [[2'-[[[(2-furanylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498578-01-1 CAPLUS

CN Carbamic acid, [[2'-[[[3-(1H-imidazol-1-yl)propyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498578-02-2 CAPLUS

CN Carbamic acid, [[2'-[[[(2-naphthalenylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498578-04-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(4-methoxyphenyl)amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)





RN 498578-05-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)





RN 498578-06-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(4-methoxyphenyl)amino]carbonyl]amino]methyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 498578-07-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(2-pyridinylmethyl)-2'--[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-08-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-2'--[[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-09-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 498578-10-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(4-chlorophenyl)amino]carbonyl]amino]methyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)





RN 498578-11-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 498578-12-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-methoxyphenyl)ethyl]-2'--[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498578-13-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-2'--[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-14-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-2'--[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-15-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-chlorophenyl)amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)





RN 498578-16-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'-[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498578-17-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 498578-18-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'--[[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-19-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[[[2,4-difluorophenyl]amino]carbonyl]amino]methyl]-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)





RN 498578-20-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(butylamino)carbonyl]amino]methyl]-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)



RN 498578-21-5 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2'-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-35-1 CAPLUS

CN Carbamic acid, [[2'-[[[(1S)-3-methyl-1-[(phenylamino)carbonyl]butyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 498578-36-2 CAPLUS

CN Carbamic acid, [[2'-[[[(1S)-3-methyl-1-[[[(phenylmethyl)amino]carbonyl]butyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 498578-37-3 CAPLUS

CN Carbamic acid, [[2'-[[[(1S)-3-methyl-1-[[[(2,2,2-trifluoroethyl)amino]carbonyl]butyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 498578-38-4 CAPLUS

CN Carbamic acid, [[2'-[[[(1S)-3-methyl-1-[[[(3-methylbutyl)amino]carbonyl]butyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 498578-39-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[4-methoxybenzoyl]amino]methyl]-N-
 [(1S)-3-methyl-1-[[[(2,2,2-trifluoroethyl)amino]carbonyl]butyl]- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 498578-40-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(1S)-3-methyl-1-[[[(2,2,2-
 trifluoroethyl)amino]carbonyl]butyl]-2'-[[[(1-oxo-3-
 phenylpropyl)amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 498578-42-0 CAPLUS



CN Carbamic acid, [[2'-[[[2-[(1-methylethyl)amino]-2-oxo-1-(2-
 pyridinylmethyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-,

phenylmethyl ester (9CI) (CA INDEX NAME)





RN 498578-44-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'--[[[3-(2-methylphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498578-45-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'--[[[3-(4-fluorophenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498578-46-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(4-methylphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498578-47-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(4-hydroxyphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-48-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(4-methoxyphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-49-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(3,4-difluorophenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)



G1 C,N

G2 COOH, NH₂, N, AkG3 Cb, Cy, Hy, Ak, CF₃

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 07:16:08 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 8095 TO ITERATE

12.4% PROCESSED 1000 ITERATIONS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 156511 TO 167289
 PROJECTED ANSWERS: 82 TO 564

L2 2 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 07:16:15 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 161548 TO ITERATE

100.0% PROCESSED 161548 ITERATIONS
 SEARCH TIME: 00.00.06

250 ANSWERS

L3 250 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST


SINCE FILE	TOTAL
ENTRY	SESSION
148.15	148.36

Patel

<4/14/2003>

compds. as potassium channel blockers)
INDEX TERM: 51171-02-9P 57841-90-4P 65423-27-0P 349085-94-5P
433969-27-8P 433969-28-9P 433969-29-0P 434319-30-9P
434319-32-1P 434319-34-3P 434319-36-5P 434319-38-7P
434319-39-8P 434319-41-2P 434319-43-4P 434319-45-6P
434319-46-7P
ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(prepn. of ortho-substituted nitrogen contg. bisaryl
compds. as potassium channel blockers)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD.
REFERENCE(S): (1) Alexander, C; WO 9804521 A 1998 CAPLUS
(2) Aventis Pharma GmbH; DE 19947457 A 2001 CAPLUS *get*
L1 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:428866 CAPLUS
DOCUMENT NUMBER: 137:20297
TITLE: Preparation of ortho-substituted and meta-substituted
bisaryl compounds as potassium channel blockers
INVENTOR(S): Peukert, Stefan; Brendel, Joachim; Hemmerle,
Horst; Kleemann, Heinz-Werner
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
INT. PATENT CLASSIF.:
MAIN: C07C271-22
SECONDARY: C07C235-34; C07D213-79; C07D213-81; C07D213-82;
A61K031-325; A61K031-4402; A61K031-4406; A61P009-06
CLASSIFICATION: 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002044137	A1	20020606	WO 2001-EP13294	20011117
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10059418	A1	20020620	DE 2000-10059418	20001130
AU 2002027931	A5	20020611	AU 2002-27931	20011117
US 2003013719	A1	20030116	US 2001-995771	20011129
PRIORITY APPLN. INFO.:			DE 2000-10059418 A	20001130
			WO 2001-EP13294 W	20011117
OTHER SOURCE(S):		MARPAT 137:20297		
GRAPHIC IMAGE:				



ABSTRACT:

Title compds. [I; A1-A8 = N, CH, CR5; whereby >4 of A1-A8 = CH; R1 = CO2R9, SO2R10, COR11, C(O)NR12R13, C(S)NR12R13; R9-R12 = CxH2xR14; x = 0-4; R14 = alkyl, cycloalkyl, CF3, C2F5, C3F7, CH2F, CHF2, OR15, SO2Me, (substituted) Ph, naphthyl, etc.; R15 = alkyl, cycloalkyl, (substituted) Ph; R13 = H, alkyl, CF3; R2 = H, alkyl, CF3; R3 = CyH2yR16, etc.; y = 0-4; R16 = alkyl, cycloalkyl, CF3, C2F5, C3F7, CH2F, CHF2, OR17, SO2Me, (substituted) Ph, naphthyl, etc.; R17 = H, alkyl, cycloalkyl, (substituted) Ph, pyridyl; R4 = H, alkyl, CF3; or R3R4 = (O-, S-, NH-, N(methyl)-, N(benzyl)-interrupted) C4-5 alkylene; R5 = F, Cl, Br, I, CF3, NO2, cyano, CO2Me, COMe, amino, OH, alkyl, alkoxy, etc.; R30, R31 = H, alkyl; or R30R31 = C2 alkylene], were prep'd. Thus, 1-[6-(2-aminomethylphenyl)pyridin-2-yl]-N-(4-methoxyphenyl)amide in CH2Cl2 was stirred with 4-methoxyphenylacetyl chloride and N-ethyldiisopropylamine overnight to give 78% 1-[6-(2-[2-(4-methoxyphenyl)acetylaminomethylphenyl]pyridin-2-yl)-N-(4-methoxyphenyl)amide. Several I inhibited Kv1.5 human channel with IC50 = 2 - <100 .mu.M.

SUPPL. TERM: phenylpyridine prepn potassium channel blocker; pyridine phenyl prepn potassium channel blocker; bisaryl compd prepn antiarrhythmic

INDEX TERM: Heart, disease
(atrial fibrillation, treatment; prepn. of ortho-substituted and meta-substituted bisaryl compds. as potassium channel blockers)

INDEX TERM: Heart, disease
(atrial flutter, treatment; prepn. of ortho-substituted and meta-substituted bisaryl compds. as potassium channel blockers)

INDEX TERM: Ion channel blockers
(potassium; prepn. of ortho-substituted and meta-substituted bisaryl compds. as potassium channel blockers)

INDEX TERM: Antiarrhythmics
Human
(prepn. of ortho-substituted and meta-substituted bisaryl compds. as potassium channel blockers)

INDEX TERM: 433969-38-1P 433969-39-2P 433969-40-5P 433969-41-6P
433969-42-7P 433969-43-8P 433969-44-9P 433969-45-0P
433969-47-2P 433969-48-3P 433969-50-7P 433969-51-8P
433969-52-9P 433969-53-0P 433969-54-1P 433969-55-2P
433969-56-3P 433969-57-4P 433969-60-9P 433969-61-0P
433969-62-1P 433969-63-2P 433969-64-3P 433969-65-4P
433969-66-5P 433969-67-6P 433969-68-7P 433969-69-8P
ROLE: PAC (Pharmacological activity); SPN (Synthetic)

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of ortho-substituted and meta-substituted bisaryl compds. as potassium channel blockers)

INDEX TERM: 4693-91-8, 4-Methoxyphenylacetyl chloride 21190-88-5
102297-41-6 160233-31-8 162356-90-3,
N-(tert-Butoxycarbonyl)-2-bromobenzylamine 184888-43-5
433969-49-4 433969-59-6

ROLE: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of ortho-substituted and meta-substituted bisaryl compds. as potassium channel blockers)

INDEX TERM: 349086-03-9P 433969-27-8P 433969-28-9P 433969-29-0P
433969-30-3P 433969-31-4P 433969-32-5P 433969-33-6P
433969-34-7P 433969-35-8P 433969-36-9P 433969-37-0P
433969-46-1P

ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP

(Preparation); RACT (Reactant or reagent)

(prepn. of ortho-substituted and meta-substituted bisaryl compds. as potassium channel blockers)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD.

REFERENCE(S): (1) Aventis Pharma GmbH; WO 0125189 A 2001 *Imp.*
(2) Brandmeier; HELVETICA CHIMICA ACTA 1994, V77(1) P70
CAPLUS
(3) Heinz-Werner, K; US 5631293 A 1997 CAPLUS *gel-*
(4) Urbahns, K; US 5670525 A 1997 CAPLUS *Imp.*

L1 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:596210 CAPLUS

DOCUMENT NUMBER: 132:3229

TITLE: Enantioselective Parallel Synthesis Using
Polymer-Supported Chiral Co(salen) Complexes

AUTHOR(S): **Peukert, Stefan**; Jacobsen, Eric N.

CORPORATE SOURCE: Department of Chemistry and Chemical Biology and
Institute for Chemistry and Cell Biology, Harvard
University, Cambridge, MA, 02138, USA

SOURCE: Organic Letters (1999), 1(8), 1245-1248

CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

CLASSIFICATION: 25-7 (Benzene, Its Derivatives, and Condensed
Benzenoid Compounds)

Section cross-reference(s): 27

OTHER SOURCE(S): CASREACT 132:3229

ABSTRACT:

The kinetic resoln. of epoxides with phenols catalyzed by a polymer-supported Co(salen) complex is applied to the first enantioselective catalytic synthesis of parallel libraries. The corresponding 1-aryloxy-2-alcs. are obtained in high yield, purity, and enantiomeric excess. Further elaboration with diversity elements provides highly efficient access to important classes of pharmacol. active compds.

SUPPL. TERM: kinetic resoln epoxide phenol; cobalt salen catalyst kinetic
resoln epoxide; aryloxy alc enantioselective prepn

INDEX TERM: Epoxides

Phenols, reactions

ROLE: RCT (Reactant); RACT (Reactant or reagent)

(Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 2942-59-8 13139-17-8 13959-02-9 30683-23-9,
3-Bromopyridine-2-carboxylic acid 119297-30-2
132901-34-9 158066-11-6 160232-14-4

ROLE: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 31638-34-3P 65423-27-0P 332378-33-3P 434319-30-9P
434319-32-1P 434319-46-7P 434319-64-9P 434319-76-3P
498577-62-1P 498577-73-4P 502169-76-8P 502169-77-9P
502169-79-1P 502169-83-7P

ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 103-71-9, Phenyl isocyanate 122-78-1, Phenylacetaldehyde
13945-54-5, Ethyl p-methoxyphenylsulfonfylcarbamate
160233-31-8

ROLE: RCT (Reactant); RACT (Reactant or reagent)

(reaction with amines; prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD.

- REFERENCE(S): (1) Abbaszadeh, M; J Chem Soc, Perkin Trans 2 1990, V12, P2081
(2) Amos, G; J Physiol (London) 1996, V491, P31 CAPLUS
(3) Ashcroft, M; Ion channels and disease 2000, P97
(4) Aventis Sa; WO 0125189 2001 CAPLUS
(5) Aventis Sa; WO 0246162 2002 CAPLUS
(6) Brandmeier, V; Helv Chim Acta 1994, V77(1), P70 CAPLUS
(7) Brandmeier, V; Tetrahedron 1989, V45(5), P1365 CAPLUS
(8) Brendel, J; Exp Opin Ther Pat 2002, V12(11), P1589 CAPLUS
(9) Bril, A; Curr Opin Pharmacol 2002, V2(2), P154 CAPLUS
(10) Courtemanche, M; Cardiovasc Res 1999, V42, P477 CAPLUS
(11) Devita, R; J Med Chem 1998, V41, P1716 CAPLUS
(12) Feng, J; Am J Physiol 1998, V275, PH1717 CAPLUS
(13) Feng, J; Circ Res 1997, V80, P572 CAPLUS
(14) Finch, H; J Chem Soc, Perkin Trans 1 1994, P1993
(15) Gerlach, U; Drugs Future 2001, V26, P473 CAPLUS
(16) Golding, A; Methods Enzymol 1992, V207, P266
(17) Guillier, F; J Org Chem 1995, V60, P292 CAPLUS
(18) Hilper, K; J Med Chem 1994, V37, P3889
(19) Icagen; WO 9804521 1998 CAPLUS
(20) Icagen; WO 9937607 1999 CAPLUS
(21) Icagen; WO 9962891 1999 CAPLUS
(22) Kannel, W; Am J Cardiol 1998, V82, P2N MEDLINE
(23) Knobloch, K; Naun Schmied Arch Pharmacol 2002, V366, P482 CAPLUS
(24) Li, G; Circ Res 1996, V78, P689 MEDLINE

- (25) Matsuda, T; Life Sci 2001, V68(17), P2017 CAPLUS
- (26) Merck & Co In; WO 0224655 2002 CAPLUS
- (27) Nattel, S; Cell Physiol Biochem 1999, V9, P217 CAPLUS
- (28) Nattel, S; Drugs 1994, V48, P345 MEDLINE
- (29) Nishida, A; Jpn J Pharmacol 2000, V82, P1
- (30) Nygren, A; Circ Res 1998, V82, P63 CAPLUS
- (31) Nygren, A; Philos Trans R Soc London A 2001, V359, P1111 CAPLUS
- (32) Pirard, B; Unpublished results
- (33) Pratt, C; Am J Cardiol 1990, V65(4), P20B MEDLINE
- (34) Schaffer, P; Pflugers Arch - Eur J Physiol 1998, V436, P457 CAPLUS
- (35) Tichy, M; Tetrahedron:Asymmetry 1998, V9, P3497 CAPLUS
- (36) Tripos Inc; UNITY Chemical Information Software, Version 4.1.1 2000
- (37) Waldo, A; Lancet 1996, V348, P7 CAPLUS
- (38) Wang, Z; Circ Res 1993, V73, P1061 CAPLUS
- (39) Watanabe, M; Tetrahedron 1987, V43(22), P5281 CAPLUS

L1 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:49604 CAPLUS

TITLE: Identification, Synthesis, and Activity of Novel Blockers of the Voltage-Gated Potassium Channel Kv1.5

AUTHOR(S): **Peukert, Stefan**; Brendel, Joachim; Pirard, Bernard; Brueggemann, Andrea; Below, Peter; Kleemann, Heinz-Werner; Hemmerle, Horst; Schmidt, Wolfgang
CORPORATE SOURCE: Medicinal Chemistry and DG Cardiovascular, Aventis Pharma Deutschland GmbH, Frankfurt/Main, D-65926, GermanySOURCE: Journal of Medicinal Chemistry (2003), 46(4), 486-498
CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

CLASSIFICATION: 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 27

GRAPHIC IMAGE:



I

ABSTRACT:

The voltage-gated potassium channel Kv1.5 is regarded as a promising target for the development of new atrial selective drugs with fewer side effects. In the present study, several ortho,ortho-disubstituted bisaryl compds., e.g. I [R1 = Me2CHCH2CH2, 2,4-F2C6H3CH2, 2-(2-pyridyl)ethyl, etc.; R2 = PhCH2OCO, 4-MeOC6H4CH2CO, PhCH2CH2, etc.] were synthesized and screened for their ability to block Kv1.5 channels expressed in *Xenopus* oocytes. The obsd. structure-activity relationship was described by a pharmacophore model that consists of three hydrophobic centers in a triangular arrangement. The hydrophobic centers are matched by a Ph or pyridyl ring of the bisaryl core and both ends of the side chains. The most potent compds. I [R1 = 2-(2-pyridyl)ethyl; R2 = PhCH2OCO, (S)-PhCHMeOCO] inhibited the Kv1.5 channel with sub-micromolar half-blocking concns. and displayed 3-fold selectivity over Kv1.3 and no significant effect on the HERG channel and sodium currents. In addn., compds. I [R1 = 2-(2-pyridyl)ethyl, R2 = PhCH2OCO; R1 = 2,4-F2C6H3CH2, R2 = 4-MeOC6H4CH2CO] have shown antiarrhythmic effects in a pig model.

SUPPL. TERM: benzamide ortho aryl prepn voltage gated potassium channel blocker; nicotinamide ortho aryl prepn voltage gated potassium channel blocker

INDEX TERM: Heart, disease
(arrhythmia; prepn. of o-[o-(aminomethyl)phenyl]arenecarb oxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: Amides
ROLE: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(aryl; prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: Structure-activity relationship
(potassium channel-blocking; prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: Antiarrhythmics
(prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: Potassium channel
ROLE: BSU (Biological study, unclassified); BIOL (Biological study)
(voltage-gated; prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 98-88-4, Benzoyl chloride 1885-14-9, Phenylchloroformate 4693-91-8, (4-Methoxyphenyl)acetyl chloride
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(N-carboxylation; prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 85-46-1, 1-Naphthylsulfonyl chloride 98-09-9, Benzenesulfonyl chloride 777-44-6 1788-10-9
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(N-sulfonylation; prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 610-94-6, Methyl 2-bromobenzoate
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(Suzuki coupling; prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 433969-27-8P 433969-29-0P
ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Suzuki coupling; prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 102297-41-6 162356-90-3
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(boronic acid prepn.; prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 35661-40-6, FMOC-L-phenylalanine 68858-20-8, FMOC-L-valine
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(coupling with Rink resin; prepn. of o-[o-

(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 772-14-5, (R)-3-Phenylbutyric acid 772-15-6, (S)-3-Phenylbutyric acid

ROLE: RCT (Reactant); RACT (Reactant or reagent) (coupling with amines; prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 107-85-7, Isopentylamine 123-51-3, Isopentyl alcohol 2706-56-1, 2-(2-Pyridyl)ethylamine 53369-71-4 72235-52-0, 2,4-Difluorobenzylamine 502169-68-8

ROLE: RCT (Reactant); RACT (Reactant or reagent) (coupling with arenecarboxylic acid; prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 2516-47-4, (Cyclopropylmethyl)amine

ROLE: RCT (Reactant); RACT (Reactant or reagent) (coupling with arenecarboxylic acids; prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 502169-66-6

ROLE: PAC (Pharmacological activity); BIOL (Biological study) (prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 502483-12-7P 502483-13-8P 502483-14-9P 502483-15-0P

ROLE: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 498577-70-1P

ROLE: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 332378-42-4P 332378-43-5P 332378-46-8P 332378-47-9P 332378-61-7P 332378-69-5P 332378-71-9P 332378-78-6P 332378-81-1P 434319-82-1P 434319-91-2P 434319-93-4P 498577-29-0P 498577-30-3P 498577-46-1P 498578-24-8P 498578-28-2P 498578-29-3P 498578-34-0P 498579-43-4P 502169-69-9P 502169-70-2P 502169-71-3P 502169-72-4P 502169-75-7P 502169-87-1P 502169-94-0P

ROLE: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

INDEX TERM: 498578-87-3P 502169-78-0P

ROLE: PEP (Physical, engineering or chemical process); PYP

(kinetic resolu. of epoxides with phenols catalyzed by a polymer-supported Co(salen) complex)

INDEX TERM: Resolution (separation)

(kinetic; kinetic resolu. of epoxides with phenols catalyzed by a polymer-supported Co(salen) complex)

INDEX TERM: 251317-37-ODP, polymer bound 251321-94-5DP, polymer bound

ROLE: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)

(kinetic resolu. of epoxides with phenols catalyzed by a polymer-supported Co(salen) complex)

INDEX TERM: 92-54-6 92-69-3, 4-Phenylphenol 95-57-8, 2-Chlorophenol 98-54-4, 4-tert-Butylphenol 99-93-4, 4-Acetylphenol 100-02-7, reactions 100-61-8, N-Methylaniline, reactions 106-41-2, 4-Bromophenol 106-88-7, Ethyloxirane 106-92-3, (Allyloxymethyl)oxirane 108-39-4, 3-Methylphenol, reactions 108-95-2, Phenol, reactions 109-89-7, Diethylamine, reactions 110-91-8, Morpholine, reactions 121-71-1, 3-Acetylphenol 150-19-6, 3-Methoxyphenol 367-12-4, 2-Fluorophenol 371-41-5, 4-Fluorophenol 402-45-9, 4-Trifluoromethylphenol 767-00-0, 4-Cyanophenol 828-27-3, 4-Trifluoromethoxyphenol 831-82-3, 4-Phenoxyphenol 2581-34-2, 3-Methyl-4-nitrophenol 3132-64-7, Epibromohydrin 7693-46-1 10353-53-4, 3-Butenyloxirane 20439-47-8 21436-03-3 31252-42-3 37942-07-7 85567-21-1 192803-37-5

ROLE: RCT (Reactant); RACT (Reactant or reagent)

(kinetic resolu. of epoxides with phenols catalyzed by a polymer-supported Co(salen) complex)

INDEX TERM: 71031-03-3P 104605-98-3P 129098-55-1P 184488-19-5P 250778-94-0P 250778-95-1P 250778-96-2P 250778-97-3P 250778-98-4P 250778-99-5P

ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(kinetic resolu. of epoxides with phenols catalyzed by a polymer-supported Co(salen) complex)

INDEX TERM: 195049-40-2P 233770-33-7P 250778-46-2P 250778-47-3P 250778-48-4P 250778-49-5P 250778-50-8P 250778-51-9P 250778-52-0P 250778-53-1P 250778-54-2P 250778-55-3P 250778-56-4P 250778-57-5P 250778-58-6P 250778-59-7P 250778-60-0P 250778-61-1P 250778-62-2P 250778-63-3P 250778-64-4P 250778-65-5P 250778-66-6P 250778-67-7P 250778-68-8P 250778-69-9P 250778-70-2P 250778-71-3P 250778-72-4P 250778-73-5P 250778-74-6P 250778-75-7P 250778-76-8P 250778-77-9P 250778-78-0P 250778-79-1P 250778-80-4P 250778-81-5P 250778-82-6P 250778-83-7P 250778-84-8P 250778-85-9P 250778-86-0P 250778-87-1P 250778-88-2P 250778-89-3P 250778-90-6P 250778-91-7P 250778-92-8P 250778-93-9P 250779-00-1P 250779-01-2P 250779-02-3P 250779-03-4P 250779-04-5P 250779-05-6P 250779-06-7P 250779-07-8P 250779-08-9P 250779-09-0P 250779-10-3P 250779-11-4P 250779-12-5P 250779-13-6P 250779-14-7P 250779-15-8P 250779-16-9P 250779-17-0P 250779-18-1P 250779-19-2P 250779-20-5P 250779-21-6P 250779-22-7P 250779-23-8P 250779-24-9P 250779-25-0P 250779-26-1P 250779-27-2P 250779-28-3P 250779-29-4P 250779-30-7P 250779-31-8P 250779-32-9P 250779-33-0P 250779-34-1P 250779-35-2P 250779-36-3P 250779-37-4P 250779-38-5P 250779-39-6P 250779-40-9P 250779-41-0P

250779-42-1P	250779-43-2P	250779-44-3P	250779-45-4P
250779-46-5P	250779-47-6P	250779-48-7P	250779-49-8P
250779-50-1P	250779-51-2P	250779-52-3P	250779-53-4P
250779-54-5P	250779-55-6P	250779-56-7P	250779-57-8P
250779-58-9P	250779-59-0P	250779-60-3P	250779-61-4P
250779-62-5P	250779-63-6P	250779-64-7P	250779-65-8P
250779-66-9P	250779-67-0P	250779-68-1P	250779-69-2P
250779-70-5P	250779-71-6P	250779-72-7P	250779-73-8P
250779-74-9P	250779-75-0P	250779-76-1P	250779-77-2P
250779-78-3P	250779-79-4P	250779-80-7P	250779-81-8P
250779-82-9P	250779-83-0P	250779-84-1P	250779-85-2P
250779-86-3P	250779-87-4P	250779-88-5P	250779-89-6P
250779-90-9P	250779-91-0P	250779-92-1P	250779-93-2P
250779-94-3P	250779-95-4P	250779-96-5P	250779-97-6P
250779-98-7P	250779-99-8P		

ROLE: SPN (Synthetic preparation); PREP (Preparation)
(kinetic resoln. of epoxides with phenols catalyzed by a
polymer-supported Co(salen) complex)

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD.

REFERENCE(S): (1) Annis, D; Angew Chem Int Ed Engl 1998, V37, P1907 CAPLUS
(2) Annis, D; J Am Chem Soc 1999, V121, P4147 CAPLUS
(3) Baker, N; Chem Pharm Bull 1995, V43, P1045 MEDLINE
(4) Booth, R; J Am Chem Soc 1997, V119, P4882 CAPLUS
(5) Chini, M; Tetrahedron Lett 1994, V35, P433 CAPLUS
(6) Crowther, A; J Med Chem 1968, V11, P1009 CAPLUS
(7) Gao, X; Chirality 1998, V10, P120 CAPLUS
(8) Jacobsen, E; Comprehensive Asymmetric Catalysis 1999,
V1-3
(9) Johnson, C; Tetrahedron 1998, V54, P4097 CAPLUS
(10) Kobayashi, S; J Am Chem Soc 1996, V118, P8977 CAPLUS
(11) Nishizawa, K; J Chem Soc Perkin Trans 1997, V2, P1293
(12) Ready, J; J Am Chem Soc 1999, V121, P6086 CAPLUS
(13) Sekar, G; J Org Chem 1999, V64, P287 CAPLUS
(14) Walsh, D; J Med Chem 1990, V33, P1823 CAPLUS
(15) Wright, J; Bioorg Med Chem Lett 1997, V7, P1377 CAPLUS

L1 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:719899 CAPLUS

DOCUMENT NUMBER: 130:66044

TITLE: The Pivaloylglycol Anchor Group: A New Platform for a
Photolabile Linker in Solid-Phase Synthesis

AUTHOR(S): Peukert, Stefan; Giese, Bernd

CORPORATE SOURCE: Department of Chemistry, University of Basel, Basel,
CH-4056, Switz.

SOURCE: Journal of Organic Chemistry (1998), 63(24), 9045-9051
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

CLASSIFICATION: 21-2 (General Organic Chemistry)

OTHER SOURCE(S): CASREACT 130:66044

ABSTRACT:

We have designed a new photolabile linker based on 2-pivaloylglycerol for the solid-phase synthesis of acids. The linker was prepd. in six steps and anchored to the support via an amide bond. Photocleavage is a two-step process, in which the immobilized acids are released by photolytic generation of a radical center and subsequent spontaneous .beta.-C,O bond scission. The

pivaloyl linker was found to cleave with high yields and purities the acids in various solvents (THF, CH₂Cl₂, dioxane, DMSO) by irradiation with light above 320 nm. Using this linker, we have demonstrated the solid-phase synthesis of test compounds by peptide synthesis, palladium-catalyzed cross coupling, and epoxidation. The linker proved to be stable toward treatment with acids and bases. The photolysis rates of our pivaloyl linker were compared with the rates of a o-nitrobenzyl photolinker and proved to be superior.

SUPPL. TERM: solid phase synthesis pivaloylglycol photolabile linker;
pivaloylglycol anchor group photolabile linker

INDEX TERM: Photolysis
Photolysis kinetics
(of pivaloylglycol anchor group used as photolabile
linker in solid-phase synthesis)

INDEX TERM: Solid phase synthesis
(use of a pivaloylglycol anchor group as photolabile
linker in solid-phase synthesis)

INDEX TERM: 217964-57-3
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and photolysis of)

INDEX TERM: 98-80-6, Phenylboronic acid 960-16-7, Tributylphenyltin
5292-43-3, tert-Butyl bromoacetate 70626-38-9 89727-88-8
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(use of a pivaloylglycol anchor group as photolabile
linker in solid-phase synthesis)

INDEX TERM: 92-92-2P, 4-Biphenylcarboxylic acid 217964-45-9P
217964-46-0P 217964-47-1P 217964-48-2P 217964-49-3P
217964-50-6P 217964-51-7DP, resin bound 217964-52-8DP,
resin bound 217964-53-9DP, resin bound 217964-54-0DP,
resin bound 217964-55-1DP, resin bound 217964-56-2DP,
resin bound 217964-58-4DP, resin bound
ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(use of a pivaloylglycol anchor group as photolabile
linker in solid-phase synthesis)

INDEX TERM: 35849-02-6P 58822-25-6P, 1-5-.beta.-Neoendorphin (human)
155180-34-0P 159262-71-2P 217964-59-5DP, resin bound
ROLE: SPN (Synthetic preparation); PREP (Preparation)
(use of a pivaloylglycol anchor group as photolabile
linker in solid-phase synthesis)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
RECORD.

REFERENCE(S): (1) Adam, W; J Am Chem Soc 1995, V117, P12578 CAPLUS
(2) Balkenhohl, F; Angew Chem Int Ed Engl 1996, V35, P2288
CAPLUS
(3) Bamford, C; J Chem Soc 1935, P1504 CAPLUS
(4) Bellof, D; Chimia 1985, V39, P317 CAPLUS
(5) Brown, B; Mol Diversity 1995, V1, P4 CAPLUS
(6) Deshpande, M; Tetrahedron Lett 1994, V35, P5613 CAPLUS
(7) Field, G; Int J Peptide Protein Res 1990, V35, P161
(8) Frobel, K; Chem Unserer Zeit 1996, V30, P270 CAPLUS
(9) Fruchtel, J; Angew Chem Int Ed Engl 1996, V35, P17
(10) Giese, B; Chem Biol 1995, V2, P367 CAPLUS
(11) Holmes, C; J Org Chem 1995, V60, P2318 CAPLUS
(12) Holmes, C; J Org Chem 1997, V62, P2370 CAPLUS
(13) Kaiser, E; Anal Biochem 1970, V34, P595 CAPLUS
(14) Lenz, R; J Am Chem Soc 1997, V119, P2784 CAPLUS
(15) Licht, S; Science 1996, V271, P477 CAPLUS

- (16) Lloyd-Williams, P; Int J Pept Protein Res 1991, V37, P58 CAPLUS
- (17) Lloyd-Williams, P; Tetrahedron 1993, V49, P11065 CAPLUS
- (18) Look, G; J Org Chem 1994, V59, P7588 CAPLUS
- (19) Matray, T; J Am Chem Soc 1994, V116, P6931 CAPLUS
- (20) Muller, S; J Am Chem Soc 1997, V119, P2795
- (21) Nicolaou, K; Angew Chem Int Ed Engl 1998, V110, P1559
- (22) Novabiochem, A; Catalog & Peptide Synthesis Handbook 1997-1998
- (23) Rich, D; J Chem Soc Chem Commun 1973, P610 CAPLUS
- (24) Rock, R; J Org Chem 1996, V61, P1526 CAPLUS
- (25) Ruhland, B; J Am Chem Soc 1996, V118, P253 CAPLUS
- (26) Ruhland, B; J Org Chem 1997, V62, P7820 CAPLUS
- (27) Sucholeiki, I; Tetrahedron Lett 1994, V35, P7307 CAPLUS
- (28) Thompson, L; Chem Rev 1996, V96, P555 CAPLUS
- (29) Von Sonntag, C; Adv Radical Biol 1981, V9, P109 CAPLUS
- (30) Wang, S; J Org Chem 1976, V41, P3258 CAPLUS

L1 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:349323 CAPLUS

DOCUMENT NUMBER: 127:91785

TITLE: ESR evidence for a heterolytic C,O-bond cleavage in models of 4'-DNA radicals

AUTHOR(S): **Peukert, Stefan**; Batra, Rohit; Giese, Bernd

CORPORATE SOURCE: Department of Chemistry, University of Basel, Basel, CH-4056, Switz.

SOURCE: Tetrahedron Letters (1997), 38(20), 3507-3510

CODEN: TELEAY; ISSN: 0040-4039


PUBLISHER: Elsevier

DOCUMENT TYPE: Journal


LANGUAGE: English

CLASSIFICATION: 6-2 (General Biochemistry)


GRAPHIC IMAGE:




I



II



III



IV

ABSTRACT:

Photolysis of ketone (I) generates allylic radical (II). The decisive step in this transformation is a heterolytic C,O-bond cleavage from radical (III) that generates radical cation (IV) from radical III. This ESR study models the anaerobic strand scission of 4'-DNA radicals.

SUPPL. TERM:

ESR model DNA radical

INDEX TERM:

ESR (electron spin resonance)

Photolysis

(ESR evidence for a heterolytic C,O-bond cleavage in models of 4'-DNA radicals)

INDEX TERM:

191940-88-2

ROLE: BSU (Biological study, unclassified); FMU (Formation, unclassified); PRP (Properties); BIOL (Biological study); FORM (Formation, nonpreparative)

(ESR evidence for a heterolytic C,O-bond cleavage in models of 4'-DNA radicals)

INDEX TERM:

191794-96-4

ROLE: RCT (Reactant); RACT (Reactant or reagent)

(ESR evidence for a heterolytic C,O-bond cleavage in models of 4'-DNA radicals)

L1 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:

1996:723113 CAPLUS

DOCUMENT NUMBER:

126:18911

TITLE:

The stereochemistry of the SE2" reaction of dienylmethylsilanes

AUTHOR(S):

Fleming, Ian; Jones, Graeme R.; Landais, Yannick; Leslie, Colin P.; Morgan, Ian T.; **Peukert, Stefan**

CORPORATE SOURCE: Department Chemistry, Cambridge, CB2 1EW, UK
SOURCE: Progress in Organosilicon Chemistry, [Jubilee
International Symposium on Organosilicon Chemistry],
10th, Poznan, Aug., 1993 (1995), Meeting Date 1993,
223-232. Editor(s): Marciniec, Bogdan; Chojnowski,
Julian. Gordon & Breach: Basel, Switz.
CODEN: 63QXA8

DOCUMENT TYPE: Conference; General Review
LANGUAGE: English
CLASSIFICATION: 29-0 (Organometallic and Organometalloidal Compounds)
ABSTRACT: A review with > 13 refs. The SE2' reaction of allyl- and allenylsilanes proves to be essentially 100% stereospecifically anti, with erosion from this figure probably identifiable with loss of stereochem. integrity in the intermediate cation. Several reactions of some dienylmethylsilanes with electrophiles establish that the high level of transfer of stereochem. information that can sometimes be achieved must be largely controlled by steric effects.

SUPPL. TERM: review stereoselective substitution cycloaddn
dienylmethylsilane; electrophilic substitution
stereoselective dienylmethylsilane review; cycloaddn dipolar
stereoselective dienylmethylsilane review; stereoelectronic
effect substitution cycloaddn dienylmethylsilane review;
allylsilane stereoselective substitution cycloaddn review;
allenylsilane stereoselective substitution cycloaddn review


INDEX TERM: Cycloaddition reaction
(dipolar, stereoselective; stereochem. of SE2" reaction
of dienylmethylsilanes)

INDEX TERM: Stereoelectronic effect
Steric effects
(in stereoselective substitution and cycloaddn. reaction
of dienylmethylsilanes)

INDEX TERM: Electrophiles
Stereochemistry
(stereochem. of SE2" reaction of dienylmethylsilanes)

INDEX TERM: Substitution reaction
(stereoselective; stereochem. of SE2" reaction of
dienylmethylsilanes)

L1 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:376526 CAPLUS
DOCUMENT NUMBER: 125:143167
TITLE: Radical-induced SN1 substitution reactions
AUTHOR(S): **Peukert, Stefan**; Giese, Bernd
CORPORATE SOURCE: Dep. of Chemistry, Univ. of Basel, Basel, CH-4056,
Switz.
SOURCE: Tetrahedron Letters (1996), 37(25), 4365-4368
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
CLASSIFICATION: 33-6 (Carbohydrates)
OTHER SOURCE(S): CASREACT 125:143167
GRAPHIC IMAGE:



ABSTRACT:

Alditols, e.g. I (R = H, R₁ = OMe; R = OMe, R₁ = H), were prepd. by photochem. solvolysis radical cation-induced SN1 substitution reaction of ketones, e.g. II.

SUPPL. TERM: photochem nucleophilic substitution ketone sugar; ketone sugar radical cation nucleophilic substitution; alditol prepn

INDEX TERM: Carbohydrates and Sugars, preparation

ROLE: SPN (Synthetic preparation); PREP (Preparation) (alditols, prepn. of alditols via radical cation-induced SN1 substitution reactions)

INDEX TERM: Substitution reaction, nucleophilic (photochem., SN1; prepn. of alditols via radical cation-induced SN1 substitution reactions)

INDEX TERM: Solvolysis (photochem., prepn. of alditols via radical cation-induced SN1 substitution reactions)

INDEX TERM: 179927-84-5 180061-53-4

ROLE: RCT (Reactant); RACT (Reactant or reagent) (prepn. of alditols via radical cation-induced SN1 substitution reactions)

INDEX TERM: 179927-86-7P 179927-87-8P 179927-88-9P 179927-89-0P 179927-90-3P 179927-91-4P 180061-51-2P 180061-54-5P 180061-55-6P

ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. of alditols via radical cation-induced SN1 substitution reactions)

INDEX TERM: 179927-85-6P 179927-92-5P 179927-93-6P 179927-94-7P 179927-95-8P 180061-52-3P 180061-56-7P 180061-57-8P 180061-58-9P

ROLE: SPN (Synthetic preparation); PREP (Preparation) (prepn. of alditols via radical cation-induced SN1 substitution reactions)

L1 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:358182 CAPLUS

DOCUMENT NUMBER: 125:114748

TITLE: Diastereoselectivity in the SE2" reaction of chiral pentadienylsilanes: a test for the relative importance of steric and electronic effects

AUTHOR(S): Flemming, Ian; Jones, Graeme R.; Kindon, Nicholas D.; Landais, Yannick; Leslie, Colin P.; Morgan, Ian T.; **Peukert, Stefan**; Sarkar, Achintya K.

CORPORATE SOURCE: Department Chemistry, Cambridge, CB2 1EW, UK

SOURCE: Journal of the Chemical Society, Perkin Transactions

1: Organic and Bio-Organic Chemistry (1996), (11),
1171-1196
CODEN: JCPRB4; ISSN: 0300-922X
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
CLASSIFICATION: 29-6 (Organometallic and Organometalloidal Compounds)
Section cross-reference(s): 23, 24
OTHER SOURCE(S): CASREACT 125:114748

ABSTRACT:

The homochiral pentadienylsilanes (3Z,5E)-(hepta-3,5-dien-2-yl)dimethyl(phenyl)silane, (3Z,5E)-(hepta-3,5-dien-2-yl)trimethylsilane, (4Z,6E)-(2-methylocta-4,6-dien-3-yl)dimethyl(phenyl)silane, and (4Z,6E)-(2-methylocta-4,6-dien-3-yl)trimethylsilane undergo Lewis acid catalyzed reactions with isobutyraldehyde and its di-Me acetal stereospecifically anti with surprisingly high levels of stereoselectivity, ca. 90:10. The pentadienylsilanes (3Z)-hexa-3,5-dien-2-yl)dimethyl(phenyl)silane, (4Z)-(2-methylhepta-4,6-dien-3-yl)dimethyl(phenyl)silane, (3Z)-(hexa-3,5-dien-2-yl)trimethylsilane, and (2Z)-(1-phenylpenta-2,4-dienyl)trimethylsilane undergo dipolar cycloaddns. to 2,2-dimethylpropanenitrile oxide regioselectively at the terminal double bond and stereoselectively anti to the silyl group to a somewhat lower extent, ca. 70:30. The pentadienylsilane (3Z,5E)-(6-cyclohexylhexa-3,5-dien-2-yl)trimethylsilane undergoes deuteriodesilylation stereospecifically anti to a lower extent still, ca. 55:45. The pentadienylsilane (3Z,5E)-(8-methyl-8-methoxyethoxymethoxynona-3,5-dien-2-yl)trimethylsilane undergoes an intramol. reaction stereospecifically anti again to the extent of about 60:40, whereas the reaction of the corresponding allylsilane (3Z)-(-6methyl-6-methoxyethoxymethoxyhept-3-en-2-yl)trimethylsilane is essentially completely anti. These results show that SE2" reactions be highly stereoselective in the anti sense, that the high level is probably best accounted for by the steric effect of the silyl group, and that when the steric effect is minimized, the stereospecificity is low, but still measurable. The pentadienylsilanes were prep'd. by aldol reactions between b-silyl esters and the appropriate .alpha.,.beta.-unsat'd. aldehyde, followed by decarboxylative elimination. The products of the SE2" reactions were identified and their stereochem. det'd. by comparison with authentic materials or by degrdn. and synthesis, using chiral auxiliaries to det. the enantiomeric purity. The products of two of the dipolar cycloaddns. were identified by degrdn. and stereospecific vinylogous Peterson elimination, but the vinylogous Peterson elimination taking place with (1RS, 2Z,4SR,6SR)-(4,6-dihydroxy-7,7-dimethyl-1-phenyloct-2-enyl)trimethylsilane and its (1SR) diastereoisomer was not stereospecific, giving (5E,7E)-2,2-dimethyl-8-phenylocta-5,7-dien-3-ol from both isomers. The stereochemistries of all the reactions are summarized.

SUPPL. TERM: diastereoselectivity electrophilic substitution chiral pentadienylsilane; steric electronic effect substitution chiral pentadienylsilane; dipolar cycloaddn chiral pentadienylsilane nitrile oxide; regiochem dipolar cycloaddn chiral pentadienyl silane

INDEX TERM: Substitution reaction, electrophilic (SE2''; diastereoselectivity in electrophilic substitution reaction of chiral pentadienylsilanes as a test for relative importance of steric and electronic effects)

INDEX TERM: Inductive effect
Regiochemistry
Stereochemistry
Steric effect

(diastereoselectivity in electrophilic substitution reaction of chiral pentadienylsilanes as a test for relative importance of steric and electronic effects)

INDEX TERM: Cycloaddition reaction
(dipolar, diastereoselectivity in electrophilic substitution reaction of chiral pentadienylsilanes as a test for relative importance of steric and electronic effects)

INDEX TERM: 3839-31-4, Dimethyl(phenyl)silyllithium
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(copper salt mediated reaction with ester)

INDEX TERM: 75-26-3, 2-Bromopropane
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(copper salt mediated reaction with pyrrolidinone)

INDEX TERM: 50652-78-3, Methyl 4-methylpent-2-enoate
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(copper salt mediated reaction with silyllithium)

INDEX TERM: 178940-30-2P
ROLE: SPN (Synthetic preparation); PREP (Preparation)
(deuteriodesilylation; diastereoselectivity in electrophilic substitution reaction of chiral pentadienylsilanes as a test for relative importance of steric and electronic effects)


INDEX TERM: 78-84-2, Isobutyraldehyde 107-02-8, 2-Propenal, reactions
599-00-8, Deuteriotrifluoroacetic acid 2043-61-0,
Cyclohexanecarboxaldehyde 5664-21-1,
Cyclohexaneacetaldehyde 18267-36-2 39741-81-6
41632-89-7, Isobutyraldehyde dimethyl acetal 98158-37-3
118087-92-6 118733-52-1 128658-80-0 178940-11-9
178940-16-4 178940-33-5 178940-34-6 178941-06-5
179090-86-9 179091-01-1
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(diastereoselectivity in electrophilic substitution reaction of chiral pentadienylsilanes as a test for relative importance of steric and electronic effects)

INDEX TERM: 37868-74-9P 77943-41-0P 106995-78-2P 116983-75-6P
118087-93-7P 118087-95-9P 118087-96-0P 118087-97-1P
118087-99-3P 118088-00-9P 118101-91-0P 144050-19-1P
144050-20-4P 164070-83-1P 171038-04-3P 178940-07-3P
178940-08-4P 178940-09-5P 178940-10-8P 178940-12-0P
178940-13-1P 178940-14-2P 178940-15-3P 178940-21-1P
178940-22-2P 178940-23-3P 178940-24-4P 178940-25-5P
178940-26-6P 178940-27-7P 178940-28-8P 178940-31-3P
178940-36-8P 178940-37-9P 178940-40-4P 178940-41-5P
178940-42-6P 178940-43-7P 178940-44-8P 178940-45-9P
178940-46-0P 178940-47-1P 178940-48-2P 178940-49-3P
178940-50-6P 178940-51-7P 178940-52-8P 178940-53-9P
178940-54-0P 178940-55-1P 178940-56-2P 178940-57-3P
178940-58-4P 178940-59-5P 178940-60-8P 178940-61-9P
178940-62-0P 178940-63-1P 178940-64-2P 178940-65-3P
178940-66-4P 178940-67-5P 178940-68-6P 178940-69-7P
178940-70-0P 178940-71-1P 178940-72-2P 178940-73-3P
178940-74-4P 178940-75-5P 178940-76-6P 178940-77-7P
178940-78-8P 178940-79-9P 178940-80-2P 178940-81-3P
178940-82-4P 178940-93-7P 178940-94-8P 178940-95-9P
178940-96-0P 178940-97-1P 178940-98-2P 178940-99-3P
178941-00-9P 178941-01-0P 178941-02-1P 178941-03-2P
178941-04-3P 178941-11-2P 178941-12-3P 179090-94-9P

179090-95-0P 179090-96-1P 179090-97-2P 179090-98-3P
179090-99-4P 179091-00-0P
ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(diastereoselectivity in electrophilic substitution
reaction of chiral pentadienylsilanes as a test for
relative importance of steric and electronic effects)
INDEX TERM: 637-91-2, 2,2-Dimethylpropanal oxime
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(dipolar cycloaddn. reaction; diastereoselectivity in
electrophilic substitution reaction of chiral
pentadienylsilanes as a test for relative importance of
steric and electronic effects)
INDEX TERM: 178940-17-5P 178940-18-6P 178940-19-7P 178940-20-0P
ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(dipolar cycloaddn. reaction; diastereoselectivity in
electrophilic substitution reaction of chiral
pentadienylsilanes as a test for relative importance of
steric and electronic effects)
INDEX TERM: 178940-92-6
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of)
INDEX TERM: 178940-32-4P
ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(prepn. of)
INDEX TERM: 3909-96-4P 67498-07-1P 101019-33-4P 110890-92-1P
118087-98-2P 149002-76-6P 149115-39-9P 164070-90-0P
178940-29-9P 178940-35-7P 178940-38-0P 178940-39-1P
178940-83-5P 178940-84-6P 178940-85-7P 178940-86-8P
178940-87-9P 178940-88-0P 178940-89-1P 178940-90-4P
178941-05-4P 178941-07-6P 178941-08-7P 178941-09-8P
178941-10-1P 179090-84-7P 179090-85-8P 179090-87-0P
179090-88-1P 179090-89-2P 179090-90-5P 179090-91-6P
179090-92-7P 179090-93-8P 179091-02-2P 179091-03-3P
ROLE: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
INDEX TERM: 6651-43-0, 1-Trimethylsiloxybuta-1,3-diene
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(reaction with dimethoxypropane)
INDEX TERM: 77-76-9, 2,2-Dimethoxypropane
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(reaction with siloxybutadiene)

L1 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1995:957184 CAPLUS
DOCUMENT NUMBER: 124:174939
TITLE: A new platform for designing ligands for asymmetric
induction in allylic alkylations
AUTHOR(S): Trost, Barry M.; Breit, Bernhard; **Peukert,**
Stefan; Zambrano, Jorge; Ziller, Joseph W.
CORPORATE SOURCE: Dep. Chem., Stanford Univ., Stanford, CA, 94305-5080,
USA
SOURCE: Angewandte Chemie, International Edition in English
(1995), 34(21), 2386-8
CODEN: ACIEAY; ISSN: 0570-0833
PUBLISHER: VCH

DOCUMENT TYPE: Journal
 LANGUAGE: English
 CLASSIFICATION: 21-2 (General Organic Chemistry)
 Section cross-reference(s): 75
 OTHER SOURCE(S): CASREACT 124:174939
 GRAPHIC IMAGE:



ABSTRACT:

Several ligands with a 2-NHC₆H₄PPh₂ linker were prepd. and tested in Pd₂(dba)₃-catalyzed allylic alkylations. E.g., diol I was treated with p-toluenesulfonyl isocyanate and the resulting soln. was added to a catalyst prepd. from Pd₂(dba)₃ and II (R = CONHC₆H₄PPh₂-2) to give 99% yield of enantiomers III and IV (6:94 III-IV). In presence of a catalyst prepd. from Pd₂(dba)₃ and II (R = NHCOC₆H₄PPh₂-2), the products were a 94:6 mixt. of III and IV (94% yield). Allylic alkylation of 6- and 7-membered ring diols and of 4-acetoxy-2-pentene were also investigated.

SUPPL. TERM: allylic alkylation asym induction palladium catalyst;
 crystal structure palladium catalyst; mol structure
 palladium catalyst

INDEX TERM: Crystal structure
 Molecular structure
 (of palladium catalyst)

INDEX TERM: Asymmetric synthesis and induction
 (prepn. of ligands for palladium-catalyzed asym. allylic
 alkylation)

INDEX TERM: Alkylation
 Alkylation catalysts
 (allylic, stereoselective, prepn. of ligands for
 palladium-catalyzed asym. allylic alkylation)

INDEX TERM: 173595-30-7P
 ROLE: PRP (Properties); SPN (Synthetic preparation); PREP
 (Preparation)
 (prepn. and crystal structure of)



INDEX TERM: 52522-40-4 138517-61-0 138517-65-4
 ROLE: CAT (Catalyst use); USES (Uses)
 (prepn. of ligands for palladium-catalyzed asym. allylic
 alkylation)

INDEX TERM: 173595-22-7P 173595-23-8P 173595-27-2P
ROLE: CAT (Catalyst use); SPN (Synthetic preparation); PREP
(Preparation); USES (Uses)
(prepn. of ligands for palladium-catalyzed asym. allylic
alkylation)

INDEX TERM: 4083-64-1, p-Toluenesulfonyl isocyanate 10500-12-6,
4-Acetoxy-2-pentene 18424-76-5, Dimethyl sodiomalonate
18531-96-9 29783-26-4 33216-00-1 35216-66-1
53762-85-9 53762-86-0 62116-54-5 65423-44-1,
2-(Diphenylphosphino)aniline 83529-40-2
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of ligands for palladium-catalyzed asym. allylic
alkylation)


INDEX TERM: 158361-26-3P 173595-25-0P 173595-26-1P
ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(prepn. of ligands for palladium-catalyzed asym. allylic
alkylation)

INDEX TERM: 138604-23-6P 138604-24-7P 170554-02-6P 173595-24-9P
173595-28-3P 173828-32-5P 173828-33-6P 173828-34-7P
173828-35-8P
ROLE: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of ligands for palladium-catalyzed asym. allylic
alkylation)




RN 498578-52-2 CAPLUS

CN Carbamic acid, [[4'-amino-2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498578-53-3 CAPLUS

CN Carbamic acid, [[4'-hydroxy-2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 498578-62-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-(cyclopropylmethyl)-2'-[[[(4-methyl-1-oxopentyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-63-5 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-(cyclopropylmethyl)-2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-65-7 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-(3-methylbutyl)-2'-[[[(phenoxyacetyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-66-8 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-(3-methylbutyl)-2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-68-0 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'--[[4-methyl-1-oxopentyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-70-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-71-5 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(3-methyl-1-oxopentyl)amino]methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 498578-72-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 498578-74-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 498578-76-0 CAPLUS



CN [1,1'-Biphenyl]-2-carboxamide, N-[(6-methyl-2-pyridinyl)methyl]-2'--[[[(3R)-3-(4-nitrophenyl)-1-oxobutyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498578-77-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(4-fluorophenyl)-2'--[[[(4-fluorophenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-80-6 CAPLUS

CN Carbamic acid, [[5'-chloro-2'--[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 498578-81-7 CAPLUS


CN Carbamic acid, [[2'-[[[(cyclopropylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1-methylbutyl ester (9CI) (CA INDEX NAME)



RN 498578-82-8 CAPLUS


CN Carbamic acid, [[2'-[[[(2-oxopropyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1S)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498578-83-9 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, cyclopropylmethyl ester (9CI) (CA INDEX NAME)




RN 498578-84-0 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 2-cyclopropylethyl ester (9CI) (CA INDEX NAME)




RN 498578-85-1 CAPLUS

CN Carbamic acid, [[2'-[[[(3-pyridinylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 2-phenylethyl ester (9CI) (CA INDEX NAME)



RN 498578-87-3 CAPLUS


CN Carbamic acid, [[2',6-dimethyl-6'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 498578-89-5 CAPLUS



CN Carbamic acid, [[2'-[[[2-(3-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1S)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 498578-92-0 CAPLUS

CN 2-Pyrimidinepropanamide, N-[[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 498578-95-3 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'--[[[(4-fluorophenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-96-4 CAPLUS



CN [1,1'-Biphenyl]-2-carboxamide, N-[(6-methyl-2-pyridinyl)methyl]-2'--[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498578-98-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'--[[[(4-hydroxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-99-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-6,6'-dimethyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)





RN 498579-00-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[3-(1-methylethoxy)propyl]- (9CI) (CA INDEX NAME)




RN 498579-01-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-cyclopentyl-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498579-04-7 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methoxypropyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 498579-07-0 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-(1,3-dimethylbutyl)-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498579-09-2 CAPLUS


CN Carbamic acid, [[2'-[[[(6-methyl-2-pyridinyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1S)-1-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498579-13-8 CAPLUS

CN Carbamic acid, [[4'-(aminosulfonyl)-2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)





RN 498579-15-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(1H-benzimidazol-2-ylmethyl)-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498579-18-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 498579-21-8 CAPLUS


CN Carbamic acid, [[2'-[[[(1H-benzimidazol-2-ylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 498579-43-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



GI

Patel

<4/14/2003>



I

AB Title compds. [I; R1 = CO₂R₉, SO₂R₁₀, COR₁₁, CONR₁₂R₁₃, CSNR₁₂R₁₃; R₉, R₁₀, R₁₁, R₁₂ = C_mH_{2m}R₁₄; m = 0-4; R₁₄ = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; m .noteq. 0 if R₁₄ = (cyclo)alkoxy, SO₂Me, or OPh; R₂ and R₁₃ = independently H, alkyl, or CF₃; R₃ = C_nH_{2n}R₁₆ or CHR₁₈R₁₉; n = 0-4; n .noteq. 0 if R₁₆ = OR₁₇, SO₂Me; R₁₇ = H, (cyclo)alkyl, (un)substituted Ph, or pyridyl, R₁₆ = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; R₁₈ = H or C_pH_{2p}R₁₆; p = 0-3; R₁₉ = CO₂H, CONH₂, CH₂OH, etc.; R₄ = H, alkyl, or CF₃; or NR₃R₄ = heterocyclyl; R₅, R₆, R₇, R₈ = independently H, halo, CF₃, NO₂, cyano, etc.; R₃₀ and R₃₁ = independently H or alkyl; CR₃₀R₃₁ = cyclopropyl; and pharmaceutically acceptable salts thereof] were prepd. Thus, 2'-aminomethylbiphenyl-2-(N-phenethyl)carboxamide (prepn. given) and NaHCO₃ in dioxane and H₂O were treated dropwise with 4-trifluoromethylbenzyl-N-succinimide carbonate (prepn. given) in dioxane followed by 12 h stirring at room temp. to give 2'-(4-trifluoromethylbenzyloxycarbonylaminomethyl)-biphenyl-2-(N-phenethyl)carboxamide. Tested I inhibited Kv1.5 potassium flow with IC₅₀ = 0.2 .mu.M - 11.3 .mu.M. Thus, I are esp. suitable as antiarrhythmic active agents, in particular for the treatment and prophylaxis of atrial arrhythmia, e.g. atrial fibrillation (AF) or atrial flutter (no data).

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2003 ACS

AN 2003:193044 CAPLUS

DN 138:187521

TI Preparation of 2'-aminomethylbiphenyl-2-carboxamides as Kv1.5 potassium channel blockers.

IN Brendel, Joachim; Schmidt, Wolfgang; Below, Peter

PA Aventis Pharma Deutschland G.m.b.H., Germany

SO PCT Int. Appl., 125 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001025189	A1	20010412	WO 2000-EP9151	20000919
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 DE 1999-19947457A 19991002
 DE 1999-19947457 19991002
 BR 2000-14465 20000919
 DE 1999-19947457A 19991002
 WO 2000-EP9151 W 20000919
 EP 1222163 A1 20020717 EP 2000-967703 20000919
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL
 DE 1999-19947457A 19991002
 WO 2000-EP9151 W 20000919
 JP 2003511363 T2 20030325 JP 2001-528137 20000919
 DE 1999-19947457A 19991002
 WO 2000-EP9151 W 20000919
 NO 2002-1398 20020320
 DE 1999-19947457A 19991002
 WO 2000-EP9151 W 20000919


PATENT FAMILY INFORMATION:

FAN 2001:239812

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19947457	A1	20010405	DE 1999-19947457	19991002
WO 2001025189	A1	20010412	WO 2000-EP9151	20000919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG DE 1999-19947457A 19991002 BR 2000-14465 20000919 DE 1999-19947457A 19991002 WO 2000-EP9151 W 20000919 EP 1222163 A1 20020717 EP 2000-967703 20000919 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL DE 1999-19947457A 19991002 WO 2000-EP9151 W 20000919 JP 2003511363 T2 20030325 JP 2001-528137 20000919 DE 1999-19947457A 19991002 WO 2000-EP9151 W 20000919 US 6531495 B1 20030311 US 2000-698078 20001030 DE 1999-19947457A 19991002 US 2000-675674 A220000929 NO 2002-1398 20020320 DE 1999-19947457A 19991002 WO 2000-EP9151 W 20000919				

FAN 2003:196948

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6531495	B1	20030311	US 2000-698078	20001030
				DE 1999-19947457A	19991002
				US 2000-675674	A220000929
	DE 19947457	A1	20010405	DE 1999-19947457	19991002
OS	MARPAT 138:187521				
IT	332378-39-9P				
	RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)				
	(antiarrhythmic; prepn. of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)				
RN	332378-39-9	CAPLUS			
CN	Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1-[4-(trifluoromethyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)				




IT **498577-28-9P**
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (antiarrhythmic; prepn. of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)

RN 498577-28-9 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1S)-1-[4-(trifluoromethyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 498578-50-0P 498578-51-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antiarrhythmic; prepn. of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)


RN 498578-50-0 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methylbutyl)amino]carbonyl]-4'-nitro[1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 498578-51-1 CAPLUS

CN Carbamic acid, [[4'-methoxy-2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 332378-34-4P 332378-35-5P 332378-36-6P
 332378-37-7P 332378-38-8P 332378-40-2P
 332378-41-3P 332378-42-4P 332378-43-5P
 332378-44-6P 332378-45-7P 332378-46-8P
 332378-47-9P 332378-48-0P 332378-49-1P
 332378-69-5P 332378-70-8P 332378-71-9P
 332378-72-0P 332378-73-1P 332378-74-2P
 332378-75-3P 332378-76-4P 332378-77-5P
 332378-78-6P 332378-79-7P 332378-80-0P
 332378-81-1P 332378-82-2P 498577-29-0P
 498577-30-3P 498577-31-4P 498577-32-5P
 498577-33-6P 498577-34-7P 498577-35-8P


498577-36-9P 498577-37-0P 498577-38-1P
498577-39-2P 498577-40-5P 498577-41-6P
498577-42-7P 498577-43-8P 498577-44-9P
498577-46-1P 498577-48-3P 498577-49-4P
498577-50-7P 498577-51-8P 498577-52-9P
498577-53-0P 498577-54-1P 498577-55-2P
498577-56-3P 498577-57-4P 498577-58-5P
498577-59-6P 498577-60-9P 498577-61-0P
498577-62-1P 498577-63-2P 498577-64-3P
498577-65-4P 498577-66-5P 498577-67-6P
498577-68-7P 498577-69-8P 498577-70-1P
498577-71-2P 498577-72-3P 498577-73-4P
498577-74-5P 498577-75-6P 498577-76-7P
498577-77-8P 498577-78-9P 498577-79-0P
498577-80-3P 498577-81-4P 498577-82-5P
498577-83-6P 498577-84-7P 498577-85-8P
498577-86-9P 498577-87-0P 498577-88-1P
498577-89-2P 498577-90-5P 498577-91-6P
498577-92-7P 498577-93-8P 498577-94-9P
498577-95-0P 498577-96-1P 498577-97-2P
498577-98-3P 498577-99-4P 498578-00-0P
498578-01-1P 498578-02-2P 498578-04-4P
498578-05-5P 498578-06-6P 498578-07-7P
498578-08-8P 498578-09-9P 498578-10-2P
498578-11-3P 498578-12-4P 498578-13-5P
498578-14-6P 498578-15-7P 498578-16-8P
498578-17-9P 498578-18-0P 498578-19-1P
498578-20-4P 498578-21-5P 498578-35-1P
498578-36-2P 498578-37-3P 498578-38-4P
498578-39-5P 498578-40-8P 498578-42-0P
498578-44-2P 498578-45-3P 498578-46-4P
498578-47-5P 498578-48-6P 498578-49-7P
498578-52-2P 498578-53-3P 498578-62-4P
498578-63-5P 498578-65-7P 498578-66-8P
498578-68-0P 498578-70-4P 498578-71-5P
498578-72-6P 498578-74-8P 498578-76-0P
498578-77-1P 498578-80-6P 498578-81-7P
498578-82-8P 498578-83-9P 498578-84-0P
498578-85-1P 498578-87-3P 498578-89-5P
498578-92-0P 498578-95-3P 498578-96-4P
498578-98-6P 498578-99-7P 498579-00-3P
498579-01-4P 498579-04-7P 498579-07-0P
498579-09-2P 498579-13-8P 498579-15-0P
498579-18-3P 498579-21-8P 498579-43-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(antiarrhythmic; prepn. of aminomethylbiphenylcarboxamides as Kv1.5
potassium channel blockers)


RN 332378-34-4 CAPLUS

CN Carbamic acid, [[2'-[[[(2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-2-
yl]methyl]-, [4-(trifluoromethyl)phenyl]methyl ester (9CI) (CA INDEX
NAME)




RN 332378-35-5 CAPLUS

CN Carbamic acid, [[2'-[[[(2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-36-6 CAPLUS

CN Carbamic acid, [[2'-[[[(2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 2-(methylsulfonyl)ethyl ester (9CI) (CA INDEX NAME)




RN 332378-37-7 CAPLUS

CN Carbamic acid, [[2'-[[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, [4-(trifluoromethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 332378-38-8 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (4-fluorophenyl)methyl ester (9CI) (CA INDEX NAME)




RN 332378-40-2 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 4,4,4-trifluorobutyl ester (9CI) (CA INDEX NAME)




RN 332378-41-3 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, butyl ester (9CI) (CA INDEX NAME)




RN 332378-42-4 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-43-5 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-44-6 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, butyl ester (9CI) (CA INDEX NAME)




RN 332378-45-7 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (2-chlorophenyl)methyl ester (9CI) (CA INDEX NAME)




RN 332378-46-8 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 332378-47-9 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 332378-48-0 CAPLUS

CN Benzoic acid, 4-[[[2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]amino]carbonyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 332378-49-1 CAPLUS

CN Carbamic acid, [[2'-[[[(2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)




RN 332378-69-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[(benzoylamino)methyl]-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 332378-70-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[(benzoylamino)methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 332378-71-9 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-(3-methylbutyl)-2'--[[[(phenylamino)carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 332378-72-0 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(phenylamino)carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 332378-73-1 CAPLUS

CN Carbamic acid, [[2'-[[methyl(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-74-2 CAPLUS

CN Carbamic acid, [[2'-[(cyclohexylamino)carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-75-3 CAPLUS

CN Carbamic acid, [[2'-[(phenylamino)carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-76-4 CAPLUS

CN Carbamic acid, [[2'-[[methyl[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-77-5 CAPLUS

CN Carbamic acid, [[2'-[[dibutylamino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-78-6 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-79-7 CAPLUS

CN Carbamic acid, [[2'-[[[(2,2,2-trifluoroethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 332378-80-0 CAPLUS


CN Carbamic acid, [[2'-[[[2-(1-oxido-2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 332378-81-1 CAPLUS

CN Carbamic acid, [[2'-[[[(1S)-1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 332378-82-2 CAPLUS

CN L-Phenylalanine, N-[[2'-[[[(phenylmethoxy)carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 498577-29-0 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1S)-1-phenylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 498577-30-3 CAPLUS


CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1R)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498577-31-4 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1-[2-(trifluoromethyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)




RN 498577-32-5 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1-[3-(trifluoromethyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)



RN 498577-33-6 CAPLUS


CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1-(2,6-difluorophenyl)ethyl ester (9CI) (CA INDEX NAME)



RN 498577-34-7 CAPLUS



CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1R)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498577-35-8 CAPLUS


CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1-[4-(trifluoromethyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)



RN 498577-36-9 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1S)-1-phenylbutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 498577-37-0 CAPLUS



CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1S)-1-phenylbutyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 498577-38-1 CAPLUS


CN Carbamic acid, [[2'-[[[2-(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (4S)-4-phenylbutyl ester (9CI) (CA INDEX NAME)






RN 498577-39-2 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 4,4,4-trifluorobutyl ester (9CI) (CA INDEX NAME)





RN 498577-40-5 CAPLUS

CN Carbamic acid, [[2'-[[[(2-pyridinylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 498577-41-6 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)





RN 498577-42-7 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 498577-43-8 CAPLUS



CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)



RN 498577-44-9 CAPLUS



CN Carbamic acid, [[2'-[[[(2-pyridinylmethyl)amino]carbonyl][1,1'-biphenyl]-2-

yl)methyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)




RN 498577-46-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498577-48-3 CAPLUS



CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 498577-49-4 CAPLUS



CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-

N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)





RN 498577-50-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 498577-51-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(4-methoxyphenyl)-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498577-52-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(4-methoxyphenyl)-2'--[[[(1-oxo-3-phenylpropyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 498577-53-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 498577-54-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 498577-55-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[3-(4-ethoxyphenyl)-1-oxopropyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 498577-56-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(1-oxo-3-phenylbutyl)amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 498577-57-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(phenylmethyl)amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 498577-58-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(1S)-1-phenylethyl]amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 498577-59-6 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[[(1R)-1-phenylethyl]amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 498577-60-9 CAPLUS

CN Carbamic acid, [[2'--[[[2-(1-oxido-4-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 498577-61-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(1-oxido-3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 498577-62-1 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-63-2 CAPLUS

CN Carbamic acid, [[2'-[[[(2-pyridinylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-64-3 CAPLUS

CN Carbamic acid, [[2'-[[[(3-pyridinylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-65-4 CAPLUS

CN Carbamic acid, [[2'-[[[2-(3-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-66-5 CAPLUS

CN Carbamic acid, [[2'-[[[2-(4-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-67-6 CAPLUS

CN Carbamic acid, [[2'-[[[4-ethylphenyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-68-7 CAPLUS

CN Carbamic acid, [[2'-[[[(4-methoxyphenyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-69-8 CAPLUS


CN Carbamic acid, [[2'-[[[(4-fluorophenyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 498577-70-1 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)






RN 498577-71-2. CAPLUS


CN Carbamic acid, [[2'-[[[(1R)-1-(hydroxymethyl)-2-phenylethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498577-72-3 CAPLUS

CN 2-Pyridinepropanoic acid, .alpha.-[[[2'-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 498577-73-4 CAPLUS


CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 498577-74-5 CAPLUS


CN Carbamic acid, [[2'-[[[(1S)-1-(aminocarbonyl)-2-methylpropyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498577-75-6 CAPLUS


CN Carbamic acid, [[2'-[[ethyl(4-pyridinylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 498577-76-7 CAPLUS


CN L-Leucine, N-[[2'-[[[(phenylmethoxy)carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498577-77-8 CAPLUS

CN Carbamic acid, [[2'-[[[(4,4,4-trifluorobutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 498577-78-9 CAPLUS

CN Carbamic acid, [[2'-[[[4-(dimethylamino)phenyl]methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 498577-79-0 CAPLUS

CN Carbamic acid, [[2'-[[[2-[(1-methylethyl)amino]-2-oxoethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 498577-80-3 CAPLUS

CN 2-Pyridinepropanoic acid, .alpha.-[[[2'-[[[(phenylmethoxy)carbonylamino]methyl]amino]carbonyl]methyl]amino]carbonyl]-1,1'-biphenyl-2-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 498577-81-4 CAPLUS

CN Carbamic acid, [[2'-[[[2-(3-pyridinyl)ethyl]amino]carbonyl] [1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 498577-82-5 CAPLUS


CN Carbamic acid, [[2'-[[[2-(4-pyridinyl)ethyl]amino]carbonyl] [1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 498577-83-6 CAPLUS


CN Carbamic acid, [[2'-[[[(1R)-1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498577-84-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-2'-[[[(phenylmethyl)amino]thioxomethyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498577-85-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(phenylamino)thioxomethyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 498577-86-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[thioxo[[3-(trifluoromethyl)phenyl]amino]methyl]amino]methyl]-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 498577-87-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(3,4-dichlorophenyl)amino]thioxomethyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 498577-88-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(phenylmethyl)amino]thioxomethyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 498577-89-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(2-phenylethyl)amino]thioxomethyl]amino]methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 498577-90-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(3-fluorophenyl)amino]thioxomethyl]amino]methyl]-N-[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 498577-91-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-2'-[[[(3-fluorophenyl)amino]thioxomethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498577-92-7 CAPLUS

CN Carbamic acid, [[2'-[[[(2-methoxyethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-93-8 CAPLUS

CN Carbamic acid, [[2'-[[[(3,4,5-trimethoxyphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-94-9 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-methoxyphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-95-0 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2,4-dichlorophenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-96-1 CAPLUS

CN Carbamic acid, [[2'-[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-97-2 CAPLUS

CN Carbamic acid, [[2'-[[[2-phenoxyethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-98-3 CAPLUS

CN Carbamic acid, [[2'-[[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498577-99-4 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-thienylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498578-00-0 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-furanylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498578-01-1 CAPLUS

CN Carbamic acid, [[2'-[[[3-(1H-imidazol-1-yl)propyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498578-02-2 CAPLUS

CN Carbamic acid, [[2'-[[[2-naphthalenylmethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498578-04-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[[(4-methoxyphenyl)amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)





RN 498578-05-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)





RN 498578-06-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[[(4-methoxyphenyl)amino]carbonyl]amino]methyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 498578-07-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(2-pyridinylmethyl)-2'--[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-08-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-2'-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-09-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 498578-10-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-chlorophenyl)amino]carbonyl]amino]methyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)





RN 498578-11-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 498578-12-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-methoxyphenyl)ethyl]-2'-[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-13-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-2'-[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-14-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-2'--[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-15-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(4-chlorophenyl)amino]carbonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)





RN 498578-16-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'--[[[(4-(trifluoromethyl)phenyl)amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498578-17-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 498578-18-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-pyridinyl)ethyl]-2'--[[[[(3-(trifluoromethyl)phenyl)amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-19-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[[(2,4-difluorophenyl)amino]carbonyl]amino]methyl]-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)





RN 498578-20-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(butylamino)carbonyl]amino]methyl]-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)



RN 498578-21-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-2'-[[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-35-1 CAPLUS

CN Carbamic acid, [[2'-[[[(1S)-3-methyl-1-[(phenylamino)carbonyl]butyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA

INDEX NAME)


Absolute stereochemistry.



RN 498578-36-2 CAPLUS

CN Carbamic acid, [[2'-[[[(1S)-3-methyl-1-[[[(phenylmethyl)amino]carbonyl]butyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 498578-37-3 CAPLUS

CN Carbamic acid, [[2'-[[[(1S)-3-methyl-1-[[[(2,2,2-trifluoroethyl)amino]carbonyl]butyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 498578-38-4 CAPLUS


CN Carbamic acid, [[2'-[[[(1S)-3-methyl-1-[[[(3-methylbutyl)amino]carbonyl]butyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 498578-39-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxybenzoyl)amino]methyl]-N-[(1S)-3-methyl-1-[[[(2,2,2-trifluoroethyl)amino]carbonyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498578-40-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(1S)-3-methyl-1-[[[(2,2,2-trifluoroethyl)amino]carbonyl]butyl]-2'-[[[(1-oxo-3-phenylpropyl)amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 498578-42-0 CAPLUS

CN Carbamic acid, [[2'-[[[2-[(1-methylethyl)amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)





RN 498578-44-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'--[[[3-(2-methylphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498578-45-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'--[[[3-(4-fluorophenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498578-46-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'--[[[3-(4-methylphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498578-47-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'--[[[3-(4-hydroxyphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498578-48-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'--[[[3-(4-methoxyphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-49-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'--[[[3-(3,4-difluorophenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-52-2 CAPLUS

CN Carbamic acid, [[4'-amino-2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 498578-53-3 CAPLUS

CN Carbamic acid, [[4'-hydroxy-2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 498578-62-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-(cyclopropylmethyl)-2'-[[(4-methyl-1-oxopentyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-63-5 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-(cyclopropylmethyl)-2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-65-7 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-(3-methylbutyl)-2'-[[(phenoxyacetyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-66-8 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-(3-methylbutyl)-2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-68-0 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'--[[4-methyl-1-oxopentyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-70-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-71-5 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(3-methyl-1-oxopentyl)amino]methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 498578-72-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 498578-74-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 498578-76-0 CAPLUS



CN [1,1'-Biphenyl]-2-carboxamide, N-[(6-methyl-2-pyridinyl)methyl]-2'-[[[(3R)-3-(4-nitrophenyl)-1-oxobutyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498578-77-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(4-fluorophenyl)-2'-[[[(4-fluorophenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-80-6 CAPLUS

CN Carbamic acid, [[5'-chloro-2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 498578-81-7 CAPLUS


CN Carbamic acid, [[2'-[[[(cyclopropylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1-methylbutyl ester (9CI) (CA INDEX NAME)



RN 498578-82-8 CAPLUS


CN Carbamic acid, [[2'-[[[(2-oxopropyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1S)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498578-83-9 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, cyclopropylmethyl ester (9CI) (CA INDEX NAME)




RN 498578-84-0 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 2-cyclopropylethyl ester (9CI) (CA INDEX NAME)




RN 498578-85-1 CAPLUS

CN Carbamic acid, [[2'-[[[(3-pyridinyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 2-phenylethyl ester (9CI) (CA INDEX NAME)



RN 498578-87-3 CAPLUS


CN Carbamic acid, [[2',6-dimethyl-6'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 498578-89-5 CAPLUS



CN Carbamic acid, [[2'-[[[2-(3-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1S)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 498578-92-0 CAPLUS

CN 2-Pyrimidinepropanamide, N-[[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 498578-95-3 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'--[[[(4-fluorophenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-96-4 CAPLUS



CN [1,1'-Biphenyl]-2-carboxamide, N-[(6-methyl-2-pyridinyl)methyl]-2'--[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498578-98-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'--[[[(4-hydroxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498578-99-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-, 6,6'-dimethyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)





RN 498579-00-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[3-(1-methylethoxy)propyl]- (9CI) (CA INDEX NAME)




RN 498579-01-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-cyclopentyl-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498579-04-7 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methoxypropyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 498579-07-0 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-(1,3-dimethylbutyl)-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498579-09-2 CAPLUS


CN Carbamic acid, [[2'-[[[(6-methyl-2-pyridinyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1S)-1-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 498579-13-8 CAPLUS

CN Carbamic acid, [[4'-(aminosulfonyl)-2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)





RN 498579-15-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(1H-benzimidazol-2-ylmethyl)-2'--[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 498579-18-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 498579-21-8 CAPLUS


CN Carbamic acid, [[2'-[[[(1H-benzimidazol-2-ylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 498579-43-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



GI

Patel

<4/14/2003>



I

AB Title compds. [I; R1 = CO₂R₉, SO₂R₁₀, COR₁₁, CONR₁₂R₁₃, CSNR₁₂R₁₃; R₉, R₁₀, R₁₁, R₁₂ = CmH_{2m}R₁₄; m = 0-4; R₁₄ = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; m .noteq. 0 if R₁₄ = (cyclo)alkoxy, SO₂Me, or OPh; R₂ and R₁₃ = independently H, alkyl, or CF₃; R₃ = CnH_{2n}R₁₆ or CHR₁₈R₁₉; n = 0-4; n .noteq. 0 if R₁₆ = OR₁₇, SO₂Me; R₁₇ = H, (cyclo)alkyl, (un)substituted Ph, or pyridyl, R₁₆ = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; R₁₈ = H or C₆H₄pR₁₆; p = 0-3; R₁₉ = CO₂H, CONH₂, CH₂OH, etc.; R₄ = H, alkyl, or CF₃; or NR₃R₄ = heterocyclyl; R₅, R₆, R₇, R₈ = independently H, halo, CF₃, NO₂, cyano, etc.; R₃₀ and R₃₁ = independently H or alkyl; CR₃₀R₃₁ = cyclopropyl; and pharmaceutically acceptable salts thereof] were prepd. Thus, 2'-aminomethylbiphenyl-2-(N-phenethyl)carboxamide (prepn. given) and NaHCO₃ in dioxane and H₂O were treated dropwise with 4-trifluoromethylbenzyl-N-succinimide carbonate (prepn. given) in dioxane followed by 12 h stirring at room temp. to give 2'-(4-trifluoromethylbenzyloxycarbonylaminoethyl)-biphenyl-2-(N-phenethyl)carboxamide. Tested I inhibited Kv1.5 potassium flow with IC₅₀ = 0.2 .mu.M - 11.3 .mu.M. Thus, I are esp. suitable as antiarrhythmic active agents, in particular for the treatment and prophylaxis of atrial arrhythmia, e.g. atrial fibrillation (AF) or atrial flutter (no data).

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2003 ACS

AN 2003:49604 CAPLUS

TI Identification, Synthesis, and Activity of Novel Blockers of the Voltage-Gated Potassium Channel Kv1.5

AU Peukert, Stefan; Brendel, Joachim; Pirard, Bernard; Brueggemann, Andrea; Below, Peter; Kleemann, Heinz-Werner; Hemmerle, Horst; Schmidt, Wolfgang

CS Medicinal Chemistry and DG Cardiovascular, Aventis Pharma Deutschland GmbH, Frankfurt/Main, D-65926, Germany

SO Journal of Medicinal Chemistry (2003), 46(4), 486-498
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English


IT 502483-12-7P 502483-13-8P 502483-14-9P
502483-15-0P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN

(Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of
the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)


RN 502483-12-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 502483-13-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 502483-14-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 502483-15-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




IT 498577-70-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)

RN 498577-70-1 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 332378-42-4P 332378-43-5P 332378-46-8P
332378-47-9P 332378-69-5P 332378-71-9P
332378-78-6P 332378-81-1P 434319-82-1P
434319-91-2P 498577-29-0P 498577-30-3P
498577-46-1P 498579-43-4P 502169-69-9P
502169-71-3P 502169-72-4P 502169-75-7P
502169-87-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)


RN 332378-42-4 CAPLUS

CN Carbamic acid, [[2'-[[[(3-methylbutyl)amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-43-5 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 332378-46-8 CAPLUS

CN Carbamic acid, [[2'-[[[3-methylbutyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 332378-47-9 CAPLUS


CN Carbamic acid, [[2'-[[[3-methylbutyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 332378-69-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'--[(benzoylamino)methyl]-N-(3-methylbutyl)-
(9CI) (CA INDEX NAME)


RN 332378-71-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(3-methylbutyl)-2'--
[[[(phenylamino)carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)

RN 332378-78-6 CAPLUS

CN Carbamic acid, [[2'--[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-


biphenyl]-2-yl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 332378-81-1 CAPLUS

CN Carbamic acid, [[2'-[[[(1S)-1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434319-82-1 CAPLUS

CN Carbamic acid, [[2-[2-[[[(3-methylbutyl)amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 434319-81-0

CMF C26 H29 N3 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 434319-91-2 CAPLUS
CN Carbamic acid, [[2-[4-[[[(3-methylbutyl)amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 498577-29-0 CAPLUS
CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1S)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 498577-30-3 CAPLUS
CN Carbamic acid, [[2'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, (1R)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498577-46-1 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'--[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498579-43-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 502169-69-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED





RN 502169-71-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(3-methylbutyl)-2'-[[2-phenylethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 502169-72-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[(4-methoxyphenyl)sulfonyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 502169-75-7 CAPLUS


CN [1,1'-Biphenyl]-2-carboxamide, 2'--[[[(3S)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 502169-74-6

CMF C31 H31 N3 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 502169-87-1 CAPLUS


CN Carbamic acid, [[2-[2-[[[(cyclopropylmethyl)amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, (1S)-1-phenylethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 434319-88-7

CMF C26 H27 N3 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 498578-87-3P 502169-78-0P

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process) (prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)


RN 498578-87-3 CAPLUS

CN Carbamic acid, [[2',6-dimethyl-6'-[[[2-(2-pyridinyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 502169-78-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



IT 434319-76-3P 498577-62-1P 498577-73-4P

502169-83-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)


RN 434319-76-3 CAPLUS

CN Carbamic acid, [[2-[2-[[[(cyclopropylmethyl)amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, 1,1-dimethylethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 434319-75-2


CMF C22 H27 N3 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 498577-62-1 CAPLUS

CN Carbamic acid, [[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 498577-73-4 CAPLUS

CN Carbamic acid, [[2'-[[[2-(2-fluorophenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 502169-83-7 CAPLUS

CN Carbamic acid, [[2'-[[[2-[[3-(3-methylbutyl)amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, 1,1-dimethylethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 434319-48-9


CMF C23 H31 N3 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2



GI



I

AB The voltage-gated potassium channel Kv1.5 is regarded as a promising target for the development of new atrial selective drugs with fewer side effects. In the present study, several ortho,ortho-disubstituted bisaryl compds., e.g. I [R1 = Me2CHCH2CH2, 2,4-F2C6H3CH2, 2-(2-pyridyl)ethyl, etc.; R2 = PhCH2OCO, 4-MeOC6H4CH2CO, PhCH2CH2, etc.] were synthesized and screened for their ability to block Kv1.5 channels expressed in *Xenopus* oocytes. The obsd. structure-activity relationship was described by a pharmacophore model that consists of three hydrophobic centers in a triangular arrangement. The hydrophobic centers are matched by a Ph or pyridyl ring of the bisaryl core and both ends of the side chains. The most potent compds. I [R1 = 2-(2-pyridyl)ethyl; R2 = PhCH2OCO, (S)-PhCHMeOCO] inhibited the Kv1.5 channel with sub-micromolar half-blocking concns. and displayed 3-fold selectivity over Kv1.3 and no significant effect on the HERG channel and sodium currents. In addn., compds. I [R1 = 2-(2-pyridyl)ethyl, R2 = PhCH2OCO; R1 = 2,4-F2C6H3CH2, R2 = 4-MeOC6H4CH2CO] have shown antiarrhythmic effects in a pig model.

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2003 ACS

AN 2002:449654 CAPLUS

DN 137:20388

TI Preparation of ortho-substituted nitrogen containing bisaryl compounds as potassium channel blockers

IN Peukert, Stefan; Brendel, Joachim; Hemmerle, Horst; Kleemann, Heinz-Werner

PA Aventis Pharma Deutschland G.m.b.H., Germany

SO PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

PATENT NO.

KIND DATE

APPLICATION NO. DATE

Patel

<4/14/2003>

PI WO 2002046162 A1 20020613 WO 2001-EP13680 20011124
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 DE 10060807 A1 20020620 DE 2000-10060807A 20001207
 AU 2002021892 A5 20020618 DE 2000-10060807 20001207
 AU 2002-21892 20011124
 DE 2000-10060807A 20001207
 WO 2001-EP13680W 20011124
 US 2003060470 A1 20030327 US 2001-2326 20011205
 DE 2000-10060807A 20001207

OS MARPAT 137:20388


IT 434319-47-8P 434319-48-9P 434319-49-0P
 434319-51-4P 434319-72-9P 434319-74-1P
 434319-76-3P 434319-78-5P 434319-80-9P
 434319-82-1P 434319-84-3P 434319-85-4P
 434319-86-5P 434319-87-6P 434319-88-7P
 434319-89-8P 434319-90-1P 434319-91-2P
 434319-92-3P 434320-00-0P 434320-02-2P
 434320-04-4P 434320-05-5P 434320-06-6P
 434320-07-7P 434320-08-8P 434320-09-9P
 434320-10-2P 434320-11-3P 434320-12-4P
 434320-13-5P 434320-14-6P 434320-15-7P
 434320-16-8P 434320-17-9P 434320-18-0P
 434320-25-9P 434320-26-0P 434320-27-1P
 434320-28-2P 434320-29-3P 434320-30-6P
 434320-31-7P 434320-32-8P 434320-33-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of ortho-substituted nitrogen contg. bisaryl compds. as potassium channel blockers)


RN 434319-47-8 CAPLUS

CN Carbamic acid, [[2-[2-[(phenylamino)carbonyl]-3-pyridinyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 434319-48-9 CAPLUS

CN Carbamic acid, [[2-[2-[[[3-methylbutyl)amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 434319-49-0 CAPLUS

CN Carbamic acid, [[2-[4-[[[3-methylbutyl)amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 434319-51-4 CAPLUS

CN Carbamic acid, [[2-[4-[[[(2,4-difluorophenyl)methyl]amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 434319-72-9 CAPLUS

CN Carbamic acid, [[2-[2-[[[2-(2-pyridinyl)ethyl]amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, 1,1-dimethylethyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 434319-71-8


CMF C25 H28 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 434319-74-1 CAPLUS

CN Carbamic acid, [[2-[2-[[[(2-pyridinylmethyl)amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, 1,1-dimethylethyl ester, trifluoroacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 434319-73-0


CMF C24 H26 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 434319-76-3 CAPLUS

CN Carbamic acid, [[2-[2-[[[(cyclopropylmethyl)amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, 1,1-dimethylethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 434319-75-2


CMF C22 H27 N3 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 434319-78-5 CAPLUS


CN Carbamic acid, [[2-[2-[[[(2S)-2-hydroxypropyl]amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, 1,1-dimethylethyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 434319-77-4

CMF C21 H27 N3 O4

Absolute stereochemistry.






CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 434319-80-9 CAPLUS


CN Carbamic acid, [[2-[2-[[[(2R)-2-hydroxypropyl]amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, 1,1-dimethylethyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 434319-79-6

CMF C21 H27 N3 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 434319-82-1 CAPLUS

CN Carbamic acid, [[2-[2-[[[(3-methylbutyl)amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 434319-81-0


CMF C26 H29 N3 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 434319-84-3 CAPLUS

CN Carbamic acid, [[2-[2-[[[2-(2-pyridinyl)ethyl]amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, (1S)-1-phenylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 434319-85-4 CAPLUS

CN Carbamic acid, [[2-[2-[[[(1S)-1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, (1S)-1-phenylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 434319-86-5 CAPLUS

CN Carbamic acid, [[2-[2-[[[(4-methoxyphenyl)amino]carbonyl]-3-pyridinyl]phenyl]methyl]-, (1S)-1-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434319-87-6 CAPLUS